Disease The intractable diseases designated by MHLW, Japan
Diseases : 338 - Clinical trials : 34,520 / Drugs : 19,957 - ( DrugBank : 2,195 ) / Drug target genes : 613 - Drug target pathways : 297
ID | Disease name [Group] | Clinical trial Phase 1 / 2 / 3 / 4 | Drug [ DrugBank ] | Target gene Target pathway | Domestic patients (1) MHLW, (2) Med expenses recipients (FY2021) |
---|---|---|---|---|---|
1 | Spinal and bulbar muscular atrophy [Neu] 💬 "Spinobulbar muscular atrophy", "SBMA", "Kennedy disease", "Kennedy-Alter-Sung syndrome" | 18 18 trials 1 / 10 / 2 / 1 💬 | 15 15 drugs [ 8 8 drugs ] | 10 10 genes 17 pathways | 1641 (1) 1,223 patients (2) 1,641 patients Age distribution💬 |
2 | Amyotrophic lateral sclerosis [Neu] 💬 "ALS" | 645 645 trials 227 / 290 / 231 / 26 💬 | 589 589 drugs [ 163 163 drugs ] | 150 150 genes 225 pathways | 9968 (1) 9,096 patients (2) 9,968 patients Age distribution💬 |
3 | Spinal muscular atrophy [Neu] 💬 "Myelopathic muscular atrophy", "Spinal muscular atrophy type I", "SMA I", "Werdnig-Hoffman disease", "Spinal muscular atrophy type II", "SMA II", "Dubowitz disease", "Spinal muscular atrophy type III", "SMA III", "Kugelberg-Welander disease", "Spinal muscular atrophy type IV", "SMA IV" | 237 237 trials 106 / 117 / 116 / 28 💬 | 123 123 drugs [ 29 29 drugs ] | 51 51 genes 75 pathways | 929 (1) 712 patients (2) 929 patients Age distribution💬 |
4 | Primary lateral sclerosis [Neu] 💬 "PLS" | 5 5 trials 2 / 2 / 0 / 1 💬 | 13 13 drugs [ 6 6 drugs ] | 13 13 genes 25 pathways | 140 (1) 175 patients (By the research group) (2) 140 patients Age distribution💬 |
5 | Progressive supranuclear palsy [Neu] 💬 "PSP" | 89 89 trials 45 / 42 / 9 / 6 💬 | 107 107 drugs [ 40 40 drugs ] | 65 65 genes 108 pathways | 12557 (1) About 8,100 patients (2) 12,557 patients Age distribution💬 |
6 | Parkinson disease [Neu] 💬 "Disease Parkinson's" | 2,307 2,307 trials 810 / 703 / 607 / 290 💬 | 2,007 2,007 drugs [ 349 349 drugs ] | 188 188 genes 199 pathways | 140473 (1) About 108,800 patients (estimated from Parkinson disease related diseases) (2) 140,473 patients Age distribution💬 |
7 | Corticobasal degeneration [Neu] 💬 "Corticobasal syndrome", "CBD" | 16 16 trials 5 / 3 / 1 / 0 💬 | 28 28 drugs [ 13 13 drugs ] | 9 9 genes 38 pathways | 4517 (1) 3,500 patients (2) 4,517 patients Age distribution💬 |
8 | Huntington disease [Neu] 💬 "Huntington chorea" | 242 242 trials 111 / 134 / 50 / 13 💬 | 205 205 drugs [ 62 62 drugs ] | 85 85 genes 159 pathways | 918 (1) 933 patients (2) 918 patients Age distribution💬 |
9 | Neuroacanthocytosis [Neu] 💬 "Choreoacanthocytosis", "Chorea-acanthocytosis", "Levine-Critchley syndrome", "McLeod syndrome", "Huntington disease-like 2", "HDL2", "Pantothenate kinase-associated neurodegeneration", "PKAN", "Hallervorden-Spatz syndrome" | 0 - | 0 - | 0 - | 35 (1) Less than 100 patients (By the research group) (2) 35 patients Age distribution💬 |
10 | Charcot-Marie-Tooth disease [Neu] 💬 "CMT", "Charcot-Marie-Tooth disease type 1", "CMT1", "Demyelinating CMT", "Charcot-Marie-Tooth disease type 2", "CMT2", "Axonal CMT", "Intermediate Charcot-Marie-Tooth disease", "CMT-I", "Intermediate CMT" | 41 41 trials 25 / 17 / 24 / 4 💬 | 46 46 drugs [ 9 9 drugs ] | 11 11 genes 15 pathways | 781 (1) 6,250 patients (By the research group) (2) 781 patients Age distribution💬 |
11 | Myasthenia gravis [Neu] 💬 "MG", "Generalized myasthenia gravis", "Generalized MG", "GMG", "Systemic myasthenia gravis", "Systemic MG", "Ocular myasthenia gravis", "Ocular MG", "OMG" | 332 332 trials 110 / 106 / 204 / 29 💬 | 234 234 drugs [ 81 81 drugs ] | 45 45 genes 127 pathways | 25568 (1) 22,998 patients (2) 25,568 patients Age distribution💬 |
12 | Congenital myasthenic syndrome [Neu] 💬 "End-plate acetylcholine receptor deficiency", "Slow-channel congenital myasthenic syndrome", "Fast-channel congenital myasthenic syndrome", "Sodium channel myasthenia", "End-plate acetylcholine esterase deficiency", "Congenital myasthenic syndrome with episodic apnoea", "Dok-7 myasthenia", "DOK7 congenital myasthenic syndrome" | 5 5 trials 1 / 0 / 0 / 0 💬 | 7 7 drugs [ 3 3 drugs ] | 5 5 genes 13 pathways | 11 (1) Less than 100 patients (By the research group) (2) 11 patients Age distribution💬 |
13 | Multiple sclerosis/Neuromyelitis optica [Neu] 💬 "Multiple sclerosis", "MS", "Neuromyelitis optica", "Neuromyelitis optica spectrum disorder", "NMOSD", "Balo concentric sclerosis", "Baló concentric sclerosis" | 3,340 3,340 trials 996 / 796 / 1256 / 514 💬 | 2,163 2,163 drugs [ 383 383 drugs ] | 241 241 genes 238 pathways | 21967 (1) 17,073 patients (2) 21,967 patients Age distribution💬 |
14 | Chronic inflammatory demyelinating polyneuropathy [Neu] 💬 "Chronic inflammatory demyelinating poly (radiculo) neuropathy", "CIDP", "Multifocal motor neuropathy" | 175 175 trials 46 / 94 / 76 / 14 💬 | 161 161 drugs [ 41 41 drugs ] | 13 13 genes 24 pathways | 5108 (1) 4,633 patients (2) 5,108 patients Age distribution💬 |
15 | Inclusion body myositis [Neu] 💬 | 42 42 trials 31 / 19 / 25 / 5 💬 | 33 33 drugs [ 11 11 drugs ] | 12 12 genes 123 pathways | 756 (1) 1,000 patients (By the research group) (2) 756 patients Age distribution💬 |
16 | Crow-Fukase syndrome [Neu] 💬 "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome" | 13 13 trials 2 / 7 / 2 / 1 💬 | 14 14 drugs [ 7 7 drugs ] | 4 4 genes 75 pathways | 223 (1) 340 patients (By the research group) (2) 223 patients Age distribution💬 |
17 | Multiple system atrophy [Neu] 💬 "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome" | 119 119 trials 43 / 40 / 40 / 7 💬 | 138 138 drugs [ 44 44 drugs ] | 59 59 genes 111 pathways | 11255 (1) 11,733 patients (2) 11,255 patients Age distribution💬 |
18 | Spinocerebellar degeneration [Neu] 💬 "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH" | 76 76 trials 20 / 46 / 19 / 5 💬 | 98 98 drugs [ 31 31 drugs ] | 44 44 genes 65 pathways | 26630 (1) 25,447 patients (2) 26,630 patients Age distribution💬 |
19 | Lysosomal storage disease [Met] 💬 "Lysosomal disease", "Gaucher disease", "Niemann-Pick disease type A/B", "Niemann-Pick type A", "NPD-A", "NPA", "Niemann-Pick type B", "NPD-B", "NPB", "Acid sphingomyelinase deficiency", "ASMD", "Niemann-Pick disease type C", "Niemann-Pick type C", "NPD-C", "NPC", "GM1-gangliosidosis", "GM1-gangliosidoses", "GM2-gangliosidosis", "GM2-gangliosidoses", "Tay-Sachs disease", "Sandhoff disease", "Krabbe disease", "Metachromatic leukodystrophy", "MLD", "Multiple-sulfatase deficiency", "Farber disease", "Mucopolysaccharidosis type I", "Mucopolysaccharidosis I", "MPS I", "Hurler syndrome", "Hurler-Scheie syndrome", "Scheie syndrome", "Mucopolysaccharidosis type II", "Mucopolysaccharidosis II", "MPS II", "Hunter syndrome", "Mucopolysaccharidosis type III", "Mucopolysaccharidosis III", "MPS III", "Sanfilippo syndrome", "Mucopolysaccharidosis type IV", "Mucopolysaccharidosis IV", "MPS IV", "MPS IVA", "Morquio syndrome", "Morquio A syndrome", "Mucopolysaccharidosis type VI", "Mucopolysaccharidosis VI", "MPS VI", "Maroteaux-Lamy syndrome", "Mucopolysaccharidosis type VII", "Mucopolysaccharidosis VII", "MPS VII", "Sly syndrome", "Mucopolysaccharidosis type IX", "Mucopolysaccharidosis IX", "MPS IX", "Hyaluronidase deficiency", "Sialidosis", "Galactosialidosis", "Mucolipidosis II", "Mucolipidosis type II", "I-cell disease", "Mucolipidosis III", "Mucolipidosis type III", "Alpha-Mannosidosis", "Alpha-Mannosidase Deficiency", "Beta-Mannosidosis", "Beta-Mannosidase Deficiency", "Fucosidosis", "Aspartylglucosaminuria", "Schindler disease", "Kanzaki disease", "Pompe disease", "Acid lipase deficiency", "Wolman disease", "Cholesterol ester storage disease", "Danon disease", "Free sialic acid storage disease", "Infantile sialic acid storage disease", "ISSD", "Salla disease", "Ceroid lipofuscinosis", "Fabry disease", "Cystinosis" | 899 899 trials 549 / 383 / 342 / 126 💬 | 684 684 drugs [ 99 99 drugs ] | 51 51 genes 182 pathways | 1582 (1) 911 patients (2) 1,582 patients Age distribution💬 |
20 | Adrenoleukodystrophy [Met] 💬 "ALD", "Childhood cerebral adrenoleukodystrophy", "Childhood cerebral ALD", "CCALD", "Adolescent cerebral adrenomyeloneuropathy", "AdolCALD", "Adrenomyeloneuropathy", "AMN", "Adult cerebral adrenoleukodystrophy", "ACALD", "Cerebellum-brain stem type adrenoleukodystrophy", "Addison-only adrenoleukodystrophy", "AO ALD", "Adrenoleukodystrophy (Female onset)" | 61 61 trials 42 / 36 / 28 / 7 💬 | 90 90 drugs [ 31 31 drugs ] | 23 23 genes 126 pathways | 252 (1) 193 patients (2) 252 patients Age distribution💬 |
21 | Mitochondrial disease [Met] 💬 | 39 39 trials 7 / 21 / 15 / 2 💬 | 42 42 drugs [ 32 32 drugs ] | 47 47 genes 67 pathways | 1608 (1) 1,087 patients (2) 1,608 patients Age distribution💬 |
22 | Moyamoya disease [Neu] 💬 "Occlusive disease in circle of Willis" | 17 17 trials 3 / 2 / 1 / 3 💬 | 22 22 drugs [ 17 17 drugs ] | 33 33 genes 45 pathways | 13431 (1) 15,177 patients (2) 13,431 patients Age distribution💬 |
23 | Prion disease [Neu] 💬 "Creutzfeldt-Jakob disease", "CJD", "Sporadic Creutzfeldt-Jakob disease", "Sporadic CJD", "sCJD", "Gerstmann-Straussler-Scheinker syndrome", "GSS", "Fatal familial insomnia", "FFI", "Environmentally acquired CJD", "Kuru disease", "Iatrogenic CJD", "iCJD", "Variant CCJD", "vCJD" | 4 4 trials 0 / 1 / 0 / 0 💬 | 5 5 drugs [ 2 2 drugs ] | 0 - | 481 (1) 584 patients (2) 481 patients Age distribution💬 |
24 | Subacute sclerosing panencephalitis [Neu] 💬 "SSPE" | 0 - | 0 - | 0 - | 66 (1) About 100 patients (2) 66 patients Age distribution💬 |
25 | Progressive multifocal leukoencephalopathy [Neu] 💬 "PML", "Leukoencephalopathy, progressive multifocal" | 26 26 trials 3 / 8 / 0 / 2 💬 | 35 35 drugs [ 22 22 drugs ] | 8 8 genes 37 pathways | 88 (1) Less than 100 patients (By the research group) (2) 88 patients Age distribution💬 |
26 | HTLV-1-associated myelopathy [Neu] 💬 "Tropical spastic paraparesis", "HTLV-1", "HTLV-I-associated myelopathy" | 29 29 trials 10 / 15 / 10 / 0 💬 | 47 47 drugs [ 29 29 drugs ] | 34 34 genes 119 pathways | 977 (1) 3,000 patients (By the research group) (2) 977 patients Age distribution💬 |
27 | Idiopathic basal ganglia calcification [Neu] 💬 "IBGC", "Fahr disease", "Familial idiopathic basal ganglia calcification", "FIBGC", "Primary familial brain calcification", "PFBC" | 1 1 trial 0 / 1 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 0 - | 127 (1) 200 patients (By the research group) (2) 127 patients Age distribution💬 |
28 | Systemic amyloidosis [Met] 💬 "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Immunoglobulin-related amyloidosis", "Reactive AA amyloidosis", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis", "Senile systemic amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "FAP" | 267 267 trials 82 / 116 / 111 / 11 💬 | 241 241 drugs [ 77 77 drugs ] | 68 68 genes 180 pathways | 4588 (1) 1,802 patients (2) 4,588 patients Age distribution💬 |
29 | Ullrich disease [Neu] 💬 "Ullrich congenital muscular dystrophy", "Collagen VI-related myopathy" | 0 - | 0 - | 0 - | 21 (1) About 300 patients (By the research group) (2) 21 patients Age distribution💬 |
30 | Distal myopathy [Neu] 💬 "Distal muscular dystrophy", "Miyoshi myopathy", "Distal dysferlinopathy", "Distal myopathy with rimmed vacuoles", "DMRV/GNE myopathy", "Oculopharyngodistal myopathy" | 15 15 trials 1 / 5 / 12 / 0 💬 | 17 17 drugs [ 3 3 drugs ] | 1 1 gene 1 pathway | 294 (1) 400 patients (By the research group) (2) 294 patients Age distribution💬 |
31 | Bethlem myopathy [Neu] 💬 "Beth Rem myopathy" | 0 - | 0 - | 0 - | 19 (1) Less than 100 patients (By the research group) (2) 19 patients Age distribution💬 |
32 | Autophagic vacuolar myopathy [Neu] 💬 "Danon disease", "X-linked myopathy with excessive autophagy", "XMEA" | 1 1 trial 1 / 0 / 0 / 0 💬 | 1 1 drug [ 0 - ] | 0 - | 9 (1) Less than 100 patients (By the research group) (2) 9 patients Age distribution💬 |
33 | Schwartz-Jampel syndrome [Neu] 💬 "Schwarz-Yanperu syndrome", "SJS", "Myotonic chondrodystrophy", "Cartilage dystrophic myotonia", "Schwartz-Jampel syndrome type 1", "SJS type 1", "Schwartz-Jampel syndrome type 2", "SJS type 2", "Stuve-Wiedemann syndrome", "Stüve-Wiedemann syndrome" | 0 - | 0 - | 0 - | 1 (1) Less than 100 patients (By the research group) (2) 1 patient Age distribution💬 |
34 | Neurofibromatosis [Skin] 💬 "Neurofibromatosis type I", "NF1", "von Recklinghausen disease", "Neurofibromatosis type II", "NF2" | 133 133 trials 54 / 85 / 15 / 8 💬 | 186 186 drugs [ 67 67 drugs ] | 79 79 genes 190 pathways | 4056 (1) 3,588 patients (2) 4,056 patients Age distribution💬 |
35 | Pemphigus [Skin] 💬 "Pemphigus vulgaris", "Pemphigus foliaceus", "Pemphigus erythematosus", "Herpetiform pemphigus", "Drug-induced pemphigus", "DIP", "Paraneoplastic pemphigus", "PNP" | 99 99 trials 44 / 36 / 49 / 7 💬 | 124 124 drugs [ 36 36 drugs ] | 23 23 genes 169 pathways | 3236 (1) About 6,000 patients (2) 3,236 patients Age distribution💬 |
36 | Epidermolysis bullosa [Skin] 💬 "Epidermolysis bullosa simplex", "EBS", "Junctional epidermolysis bullosa", "JEB", "Junctional epidermolysis bullosa type Herlitz", "JEB-H", "Junctional epidermolysis bullosa type non-Herlitz", "JEB-nH", "Dominant dystrophic epidermolysis bullosa", "DDEB", "Dystrophic epidermolysis bullosa", "DEB", "Epidermolysis bullosa dystrophica", "Recessive dystrophic epidermolysis bullosa", "RDEB", "Kindler syndrome" | 163 163 trials 117 / 99 / 53 / 16 💬 | 185 185 drugs [ 46 46 drugs ] | 50 50 genes 125 pathways | 290 (1) 347 patients (2) 290 patients Age distribution💬 |
37 | Generalised pustular psoriasis [Skin] 💬 "Pustular psoriasis", "Acute generalised pustular psoriasis, von Zumbusch type", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities", "Infantile generalized pustular psoriasis", "Pediatric generalized pustular psoriasis" | 79 79 trials 27 / 30 / 39 / 8 💬 | 57 57 drugs [ 21 21 drugs ] | 20 20 genes 102 pathways | 2070 (1) 2,072 patients (2) 2,070 patients Age distribution💬 |
38 | Stevens-Johnson syndrome [Skin] 💬 "SJS", "Mucocutaneous ocular syndrome" | 17 17 trials 11 / 11 / 4 / 2 💬 | 29 29 drugs [ 9 9 drugs ] | 15 15 genes 101 pathways | 169 (1) About 1,500 patients (2) 169 patients Age distribution💬 |
39 | Toxic epidermal necrolysis [Skin] 💬 "Toxic epidermal necrosis", "TEN" | 13 13 trials 5 / 8 / 2 / 1 💬 | 19 19 drugs [ 8 8 drugs ] | 11 11 genes 103 pathways | 70 (1) About 200 patients (2) 70 patients Age distribution💬 |
40 | Takayasu arteritis [Imm] 💬 "Aortitis syndrome", "Pulseless disease" | 24 24 trials 0 / 5 / 8 / 3 💬 | 40 40 drugs [ 18 18 drugs ] | 23 23 genes 110 pathways | 4587 (1) About 7,000 patients (2) 4,587 patients Age distribution💬 |
41 | Giant cell arteritis [Imm] 💬 "Temporal arteritis" | 131 131 trials 60 / 42 / 79 / 15 💬 | 139 139 drugs [ 36 36 drugs ] | 33 33 genes 125 pathways | 2066 (1) About 700 patients (By the research group) (2) 2,066 patients Age distribution💬 |
42 | Polyarteritis nodosa [Imm] 💬 "PAN" | 15 15 trials 0 / 6 / 6 / 2 💬 | 26 26 drugs [ 16 16 drugs ] | 26 26 genes 105 pathways | 2186 (1) [Disease ID 42-43 total] 9,610 patients (2) 2,186 patients Age distribution💬 |
43 | Microscopic polyangiitis [Imm] 💬 "MPA" | 88 88 trials 61 / 44 / 42 / 21 💬 | 81 81 drugs [ 21 21 drugs ] | 15 15 genes 90 pathways | 10626 (1) [Disease ID 42-43 total] 9,610 patients (2) 10,626 patients Age distribution💬 |
44 | Wegener granulomatosis [Imm] 💬 "Multiple vasculitis granulomatous disease", "Granulomatosis with polyangiitis" | 98 98 trials 67 / 40 / 54 / 21 💬 | 108 108 drugs [ 28 28 drugs ] | 22 22 genes 81 pathways | 3223 (1) 1,942 patients (2) 3,223 patients Age distribution💬 |
45 | Eosinophilic granulomatosis with Polyangiitis [Imm] 💬 "EGPA", "Eosinophilic multiple vasculitis granulomatous disease", "Allergic granulomatous angiitis", "AGA", "Churg-Strauss syndrome", "CSS" | 31 31 trials 8 / 7 / 16 / 5 💬 | 44 44 drugs [ 18 18 drugs ] | 18 18 genes 101 pathways | 5839 (1) About 1,800 patients (By the research group) (2) 5,839 patients Age distribution💬 |
46 | Malignant rheumatoid arthritis [Imm] 💬 "MRA", "Rheumatoid vasculitis", "RV", "Rheumatoid arthritis", "RA", "Systemic rheumatoid vasculitis", "SRV", "Malignant rheumatoid arthritis with peripheral arteritis" | 4,356 4,356 trials 1358 / 1018 / 1235 / 670 💬 | 2,567 2,567 drugs [ 415 415 drugs ] | 192 192 genes 228 pathways | 5075 (1) 6,255 patients (2) 5,075 patients Age distribution💬 |
47 | Buerger disease [Imm] 💬 "Thromboangiitis obliterans" | 9 9 trials 0 / 3 / 1 / 0 💬 | 14 14 drugs [ 7 7 drugs ] | 5 5 genes 16 pathways | 1858 (1) 7,109 patients (2) 1,858 patients Age distribution💬 |
48 | Primary antiphospholipid syndrome [Imm] 💬 "Primary antiphospholipid antibody syndrome", "Primary APS", "PAPS" | 5 5 trials 1 / 2 / 1 / 0 💬 | 6 6 drugs [ 4 4 drugs ] | 1 1 gene 7 pathways | 892 (1) About 10,000 patients (By the research group) (2) 892 patients Age distribution💬 |
49 | Systemic lupus erythematosus [Imm] 💬 "SLE" | 993 993 trials 415 / 404 / 286 / 118 💬 | 702 702 drugs [ 184 184 drugs ] | 116 116 genes 200 pathways | 64304 (1) 60,122 patients (2) 64,304 patients Age distribution💬 |
50 | Dermatomyositis [Imm] 💬 "Polymyositis" | 194 194 trials 54 / 83 / 61 / 17 💬 | 244 244 drugs [ 89 89 drugs ] | 50 50 genes 151 pathways | 25259 (1) About 19,500 patients (2) 25,259 patients Age distribution💬 |
51 | Scleroderma [Skin] 💬 "Systemic sclerosis", "SSc", "Diffuse cutaneous SSc", "dcSSc", "Limited cutaneous SSc", "lcSSc" | 525 525 trials 274 / 260 / 151 / 63 💬 | 565 565 drugs [ 148 148 drugs ] | 114 114 genes 217 pathways | 26851 (1) About 20,000 patients estimated though the latest number of patients unknown (2) 26,851 patients Age distribution💬 |
52 | Mixed connective tissue disease [Skin] 💬 [Imm] 💬 | 8 8 trials 0 / 5 / 1 / 0 💬 | 7 7 drugs [ 3 3 drugs ] | 1 1 gene 1 pathway | 10009 (1) 11,005 patients (2) 10,009 patients Age distribution💬 |
53 | Sjogren syndrome [Imm] 💬 "Sjögren syndrome", "Syndrome Sjogren's", "SS", "Autoimmune exocrinopathy", "Primary Sjogren syndrome", "Primary Sjögren syndrome", "pSS", "Secondary Sjogren syndrome", "Secondary Sjögren syndrome", "sSS" | 305 305 trials 82 / 190 / 40 / 34 💬 | 325 325 drugs [ 104 104 drugs ] | 58 58 genes 188 pathways | 18118 (1) About 66,300 patients (By the research group) (2) 18,118 patients Age distribution💬 |
54 | Adult still disease [Imm] 💬 "Adult-onset Stills disease" | 2 2 trials 0 / 0 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 1 1 gene 12 pathways | 4206 (1) About 4,800 patients (By the research group) (2) 4,206 patients Age distribution💬 |
55 | Relapsing polychondritis [Imm] 💬 | 8 8 trials 1 / 4 / 0 / 0 💬 | 10 10 drugs [ 9 9 drugs ] | 12 12 genes 101 pathways | 936 (1) About 500 patients (By the research group) (2) 936 patients Age distribution💬 |
56 | Behcet disease [Imm] 💬 "Behçet disease", "BD", "Complete Behcet disease", "Complete Behçet disease", "CBD", "Incomplete Behcet disease", "Incomplete Behçet disease", "Special-type Behcet disease", "Special-type Behçet disease", "Special-type BD" | 81 81 trials 10 / 20 / 26 / 6 💬 | 107 107 drugs [ 30 30 drugs ] | 36 36 genes 116 pathways | 15122 (1) 20,035 patients (2) 15,122 patients Age distribution💬 |
57 | Idiopathic dilated cardiomyopathy [Card] 💬 | 11 11 trials 3 / 6 / 1 / 3 💬 | 23 23 drugs [ 12 12 drugs ] | 9 9 genes 35 pathways | 18724 (1) 27,968 patients (2) 18,724 patients Age distribution💬 |
58 | Hypertrophic cardiomyopathy [Card] 💬 "HCM", "Nonobstructive hypertrophic cardiomyopathy", "Nonobstructive HCM", "Obstructive hypertrophic cardiomyopathy", "Obstructive HCM", "OHCM", "Hypertrophic obstructive cardiomyopathy", "HOCM", "Mid-ventricular obstructive hypertrophic cardiomyopathy", "MVOHCM", "Mid-ventricular hypertrophic obstructive cardiomyopathy", "MVHOCM", "Apical hypertrophic cardiomyopathy", "APH", "Expansion phase hypertrophic cardiomyopathy" | 126 126 trials 21 / 55 / 43 / 14 💬 | 135 135 drugs [ 42 42 drugs ] | 46 46 genes 162 pathways | 4201 (1) 4,667 patients (2) 4,201 patients Age distribution💬 |
59 | Restricted cardiomyopathy [Card] 💬 "Restrictive cardiomyopathy", "Constrictive cardiomyopathy" | 0 - | 0 - | 0 - | 60 (1) 50 patients (2) 60 patients Age distribution💬 |
60 | Aplastic anemia [Hem] 💬 "Idiopathic aplastic anemia", "Secondary aplastic anemia", "Special-type aplastic anemia", "Congenital aplastic anemia" | 245 245 trials 53 / 143 / 30 / 21 💬 | 318 318 drugs [ 86 86 drugs ] | 44 44 genes 166 pathways | 8348 (1) 10,287 patients (2) 8,348 patients Age distribution💬 |
61 | Autoimmune hemolytic anemia [Hem] 💬 "AIHA", "Warm AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "Mixed AIHA", "MAIHA", "Evans syndrome" | 146 146 trials 29 / 69 / 68 / 6 💬 | 131 131 drugs [ 59 59 drugs ] | 28 28 genes 158 pathways | 1178 (1) About 2,600 patients (2) 1,178 patients Age distribution💬 |
62 | Paroxysmal nocturnal hemoglobinuria [Hem] 💬 "PNH", "Classic paroxysmal nocturnal hemoglobinuria", "Classic PNH", "Paroxysmal nocturnal hemoglobinuria, bone marrow failure type", "Paroxysmal nocturnal hemoglobinuria, mixed type" | 292 292 trials 107 / 106 / 174 / 23 💬 | 151 151 drugs [ 49 49 drugs ] | 22 22 genes 108 pathways | 959 (1) About 400 patients (2) 959 patients Age distribution💬 |
63 | Idiopathic thrombocytopenic purpura [Hem] 💬 "Primary immune thrombocytopenia" | 391 391 trials 148 / 85 / 191 / 61 💬 | 235 235 drugs [ 50 50 drugs ] | 49 49 genes 139 pathways | 16972 (1) 24,956 patients (2) 16,972 patients Age distribution💬 |
64 | Thrombotic thrombocytopenic purpura [Hem] 💬 "TTP", "Upshaw-Schulman syndrome", "USS", "Acquired TTP", "Congenital TTP" | 92 92 trials 29 / 31 / 50 / 8 💬 | 85 85 drugs [ 21 21 drugs ] | 18 18 genes 76 pathways | 361 (1) Estimated occurrence: About 500 patients per year (2) 361 patients Age distribution💬 |
65 | Primary immunodeficiency [Hem] 💬 "X-linked severe combined immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase deficiency", "CD8 deficiency", "ZAP-70 deficiency", "MHC class I deficiency", "MHC class II deficiency", "Combined immunodeficiency", "Wiskott-Aldrich syndrome", "WAS", "Ataxia telangiectasia", "Nijmegen breakage syndrome", "Bloom syndrome", "Immunodeficiency, centromere region instability, facial anomalies syndrome", "ICF syndrome", "PMS2 deficiency", "Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome", "RIDDLE syndrome", "Schimke syndrome", "Netherton syndrome", "Thymic hypoplasia", "DiGeorge syndrome", "22q11.2 deletion syndrome", "Hyper-IgE syndrome", "Hepatic venoocclusive immunodeficiency", "Immunodeficiency with central hepatic vein atresia", "Dyskeratosis congenita", "X-linked agammaglobulinaemia", "Common variable immunodeficiency", "Hyper-IgM syndrome", "Isolated IgG subclass deficiency", "Selective IgA deficiency", "Specific antibody production deficiency", "Infant transient hypogammaglobulinemia", "Chédiak-Higashi syndrome", "Chediak-Higashi syndrome", "X-linked lymphoproliferative syndrome", "SAP deficiency", "SH2D1A/SLAM-associated protein deficiency", "XIAP deficiency", "X-linked inhibitor of apoptosis deficiency", "Autoimmune lymphoproliferative syndrome", "ALPS", "Familial hemophagocytic syndrome", "Perforin deficiency", "Munc13-4 deficiency", "Syntaxin 11 deficiency", "Munc18-2 deficiency", "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy", "APECED", "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", "IPEX syndrome", "CD25 deficiency", "ITCH deficiency", "Primary phagocytic dysfunction", "Severe congenital neutropenia", "Cyclic neutropenia", "Hermanskyi-Pudlak syndrome type 2", "Hermanskyi-Pudlak syndrome 2", "Griscelli syndrome type 2", "Griscelli syndrome 2", "p14 deficiency", "Warts, hypogammaglobulinemia, infections, myelokathexis syndrome", "WHIM syndrome", "Glycogen storage disease type Ib", "Leukocyte adhesion deficiency", "Shwachman-Diamond syndrome", "Chronic granulomatous disease", "Myeloperoxidase deficiency", "Mendelian susceptibility to mycobacterial disease", "MSMD", "Anhidrotic ectodermal dysplasia with immunodeficiency", "EDA-ID", "Interleukin-1 receptor-associated kinase-4 deficiency", "IRAK4 deficiency", "MyD88 deficiency", "Chronic mucocutaneous candidiasis", "Epidermodysplasia verruciformis", "Herpes simplex encephalitis", "Caspase recruitment domain family member 9 deficiency", "CARD9 deficiency", "Trypanosomiasis", "Congenital complement deficiency", "C1q deficiency", "C1r deficiency", "C1s deficiency", "C2 deficiency", "C3 deficiency", "C4 deficiency", "C5 deficiency", "C6 deficiency", "C7 deficiency", "C8 deficiency", "C9 deficiency", "Factor D deficiency", "Properdin deficiency", "Factor I deficiency", "Factor H deficiency", "MASP1 deficiency", "3MC syndrome", "Mannose-binding protein-associated serine protease 2 deficiency", "MASP2 deficiency", "Immunodeficiency associated with FCN3 mutation", "FCN3", "Hereditary angioedema type 1", "Hereditary angioedema type I", "C1 inhibitor deficiency type 1", "C1 inhibitor deficiency type I", "Hereditary angioedema type 2", "Hereditary angioedema type II", "C1 inhibitor deficiency type 2", "C1 inhibitor deficiency type II", "Hereditary angioedema type 3", "Hereditary angioedema type III", "C1 inhibitor deficiency type 3", "C1 inhibitor deficiency type III" | 500 500 trials 211 / 205 / 173 / 59 💬 | 614 614 drugs [ 119 119 drugs ] | 92 92 genes 217 pathways | 1964 (1) 1,383 patients (2) 1,964 patients Age distribution💬 |
66 | IgA nephropathy [Kid] 💬 "IgA nephritis", "Berger disease", "IgA-IgG nephropathy" | 275 275 trials 30 / 87 / 97 / 30 💬 | 258 258 drugs [ 82 82 drugs ] | 36 36 genes 140 pathways | 12447 (1) About 33,000 patients (By the research group) (2) 12,447 patients Age distribution💬 |
67 | Polycystic kidney disease [Kid] 💬 "PKD", "PCKD", "Polycystic kidney", "Autosomal dominant PKD", "ADPKD", "Autosomal recessive PKD", "ARPKD" | 221 221 trials 97 / 78 / 110 / 29 💬 | 212 212 drugs [ 55 55 drugs ] | 40 40 genes 151 pathways | 12164 (1) About 31,000 patients (By the research group) (2) 12,164 patients Age distribution💬 |
68 | Ossification of the ligamentum flavum [Bone] 💬 "Ossification of ligamentum flavum", "OLF" | 2 2 trials 0 / 0 / 0 / 0 💬 | 4 4 drugs [ 4 4 drugs ] | 1 1 gene 3 pathways | 6104 (1) 2,360 patients (2) 6,104 patients Age distribution💬 |
69 | Ossification of posterior longitudinal ligament [Bone] 💬 | 2 2 trials 0 / 0 / 0 / 0 💬 | 2 2 drugs [ 3 3 drugs ] | 0 - | 32406 (1) 33,346 patients (2) 32,406 patients Age distribution💬 |
70 | Spinal stenosis [Bone] 💬 "Extensive spinal canal stenosis" | 95 95 trials 14 / 13 / 8 / 29 💬 | 169 169 drugs [ 61 61 drugs ] | 68 68 genes 90 pathways | 5000 (1) 5,944 patients (2) 5,000 patients Age distribution💬 |
71 | Idiopathic osteonecrosis of the femoral head [Bone] 💬 "Idiopathic femoral head necrosis" | 2 2 trials 0 / 1 / 0 / 0 💬 | 3 3 drugs [ 3 3 drugs ] | 3 3 genes 7 pathways | 18817 (1) 15,388 patients (2) 18,817 patients Age distribution💬 |
72 | Pituitary ADH secretion disorder [Endo] 💬 "Inappropriate antidiuretic hormone secretion", "Syndrome of inappropriate secretion of antidiuretic hormone", "Inappropriate ADH syndrome", "Syndrome of inappropriate ADH", "Central diabetes insipidus", "Syndrome of inappropriate secretion of ADH", "SIADH" | 41 41 trials 2 / 8 / 16 / 3 💬 | 27 27 drugs [ 8 8 drugs ] | 7 7 genes 10 pathways | 3701 (1) [Disease ID 72-78 total] 17,069 patients (2) 3,701 patients Age distribution💬 |
73 | TSH-secreting pituitary adenoma [Endo] 💬 "Pituitary TSH secretion hyperthyroidism" | 1 1 trial 0 / 0 / 1 / 0 💬 | 3 3 drugs [ 2 2 drugs ] | 0 - | 173 (1) [Disease ID 72-78 total] 17,069 patients (2) 173 patients Age distribution💬 |
74 | Prolactin secreting pituitary adenoma [Endo] 💬 "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma" | 19 19 trials 3 / 6 / 1 / 1 💬 | 28 28 drugs [ 10 10 drugs ] | 14 14 genes 65 pathways | 2177 (1) [Disease ID 72-78 total] 17,069 patients (2) 2,177 patients Age distribution💬 |
75 | Cushing disease [Endo] 💬 "Cushing" | 205 205 trials 126 / 86 / 92 / 38 💬 | 176 176 drugs [ 45 45 drugs ] | 61 61 genes 127 pathways | 911 (1) [Disease ID 72-78 total] 17,069 patients (2) 911 patients Age distribution💬 |
76 | Pituitary gonadotropin secretion hyperthyroidism [Endo] 💬 "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma" | 29 29 trials 0 / 0 / 10 / 8 💬 | 44 44 drugs [ 14 14 drugs ] | 5 5 genes 15 pathways | 36 (1) [Disease ID 72-78 total] 17,069 patients (2) 36 patients Age distribution💬 |
77 | Growth hormone secreting pituitary adenoma [Endo] 💬 "Pituitary growth hormone secretion hyperthyroidism" | 1 1 trial 0 / 0 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 2 2 genes 20 pathways | 4388 (1) [Disease ID 72-78 total] 17,069 patients (2) 4,388 patients Age distribution💬 |
78 | Hypopituitarism [Endo] 💬 "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "Childhood GHD", "Childhood-onset GHD", "CGHD", "Adult GHD", "Adult-onset GHD", "AGHD", "Prolactin deficiency", "PRL deficiency" | 492 492 trials 130 / 105 / 159 / 65 💬 | 341 341 drugs [ 47 47 drugs ] | 45 45 genes 100 pathways | 19006 (1) [Disease ID 72-78 total] 17,069 patients (2) 19,006 patients Age distribution💬 |
79 | Homozygous familial hypercholesterolemia [Met] 💬 | 145 145 trials 51 / 42 / 94 / 10 💬 | 114 114 drugs [ 26 26 drugs ] | 8 8 genes 17 pathways | 371 (1) 140 patients (2) 371 patients Age distribution💬 |
80 | Resistance to thyroid hormone [Endo] 💬 "Syndrome of resistance to thyroid hormone", "Thyroid hormone insensitivity syndrome", "Refetoff syndrome", "RTH" | 1 1 trial 1 / 0 / 0 / 0 💬 | 5 5 drugs [ 3 3 drugs ] | 3 3 genes 3 pathways | 45 (1) About 3,000 patients (By the research group) (2) 45 patients Age distribution💬 |
81 | Congenital adrenal hyperplasia [Endo] 💬 "CAH", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "21-OHD", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency" | 87 87 trials 30 / 40 / 39 / 6 💬 | 87 87 drugs [ 23 23 drugs ] | 12 12 genes 68 pathways | 945 (1) About 1,800 patients (2) 945 patients Age distribution💬 |
82 | Congenital adrenal hypoplasia [Endo] 💬 "X-linked congenital adrenal hypoplasia", "DAX-1 deficiency", "Congenital adrenal hypoplasia, autosomal recessive form", "Steroidogenic factor-1 deficiency", "SF-1 deficiency", "SF-1/Ad4BP deficiency", "IMAGe syndrome" | 0 - | 0 - | 0 - | 52 (1) About 1,000 patients (2) 52 patients Age distribution💬 |
83 | Addison disease [Endo] 💬 "Primary chronic adrenocortical insufficiency", "Autoimmune polyglandular syndrome", "Hypoparathyroidism-Addison-Monilia syndrome", "HAM syndrome", "Schmidt syndrome" | 20 20 trials 6 / 5 / 3 / 6 💬 | 39 39 drugs [ 13 13 drugs ] | 6 6 genes 18 pathways | 327 (1) About 1,000 patients (By the research group) (2) 327 patients Age distribution💬 |
84 | Sarcoidosis [Resp] 💬 | 149 149 trials 52 / 70 / 31 / 25 💬 | 202 202 drugs [ 78 78 drugs ] | 66 66 genes 169 pathways | 15655 (1) 26,763 patients (2) 15,655 patients Age distribution💬 |
85 | Idiopathic interstitial pneumonia [Resp] 💬 "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "Cryptogenic organizing pneumonia", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP" | 627 627 trials 216 / 257 / 167 / 59 💬 | 443 443 drugs [ 120 120 drugs ] | 99 99 genes 212 pathways | 17665 (1) More than about 15,000 patients (Medical care eligibility certificate holders in fiscal year 2,014: 8,846 patients) (2) 17,665 patients Age distribution💬 |
86 | Pulmonary arterial hypertension [Resp] 💬 "PAH", "IPAH", "HPAH", "Eisenmenger syndrome" | 1,205 1,205 trials 404 / 309 / 485 / 170 💬 | 684 684 drugs [ 124 124 drugs ] | 100 100 genes 193 pathways | 4319 (1) 2,299 patients (2) 4,319 patients Age distribution💬 |
87 | Pulmonary veno-occlusive disease [Resp] 💬 "Pulmonary capillary hemangiomatosis", "PVOD", "PCH" | 3 3 trials 1 / 1 / 0 / 0 💬 | 4 4 drugs [ 3 3 drugs ] | 4 4 genes 45 pathways | 24 (1) About 100 patients (2) 24 patients Age distribution💬 |
88 | Chronic thromboembolic pulmonary hypertension [Resp] 💬 "CTEPH", "Idiopathic chronic pulmonary thromboembolism" | 157 157 trials 77 / 51 / 70 / 18 💬 | 107 107 drugs [ 22 22 drugs ] | 14 14 genes 54 pathways | 4843 (1) 1,810 patients (2) 4,843 patients Age distribution💬 |
89 | Lymphangioleiomyomatosis [Resp] 💬 "LAM", "Sporadic lymphangioleiomyomatosis", "Sporadic LAM", "Lymphangioleiomyomatosis with tuberous sclerosis", "TSC-LAM" | 38 38 trials 14 / 18 / 8 / 2 💬 | 38 38 drugs [ 15 15 drugs ] | 18 18 genes 118 pathways | 912 (1) 689 patients (2) 912 patients Age distribution💬 |
90 | Retinitis pigmentosa [Eye] 💬 "Rod dystrophy", "Cone-rod dystrophy", "Rod-Cone Dystrophy" | 147 147 trials 99 / 76 / 50 / 9 💬 | 176 176 drugs [ 43 43 drugs ] | 49 49 genes 110 pathways | 22223 (1) 27,158 patients (2) 22,223 patients Age distribution💬 |
91 | Budd-Chiari syndrome [Gast] 💬 "BCS", "Primary Budd-Chiari syndrome", "Secondary Budd-Chiari syndrome" | 4 4 trials 0 / 0 / 0 / 1 💬 | 5 5 drugs [ 4 4 drugs ] | 4 4 genes 14 pathways | 218 (1) 293 patients (2) 218 patients Age distribution💬 |
92 | Idiopathic portal hypertension [Gast] 💬 "Banti syndrome" | 0 - | 0 - | 0 - | 301 (1) About 1,000 patients (2) 301 patients Age distribution💬 |
93 | Primary biliary cholangitis [Gast] 💬 "Primary biliary cirrhosis", "PBC", "Asymptomatic primary biliary cholangitis", "Asymptomatic rimary biliary cirrhosis", "aPBC", "Symptomatic primary biliary cholangitis", "Symptomatic primary biliary cirrhosis", "sPBC" | 298 298 trials 148 / 136 / 110 / 64 💬 | 252 252 drugs [ 59 59 drugs ] | 35 35 genes 115 pathways | 16996 (1) 19,701 patients (2) 16,996 patients Age distribution💬 |
94 | Primary sclerosing cholangitis [Gast] 💬 "PSC", "Intrahepatic primary sclerosing cholangitis", "Intrahepatic PSC", "Extrahepatic primary sclerosing cholangitis", "Extrahepatic PSC", "Intrahepatic and extrahepatic primary sclerosing cholangitis", "Intrahepatic and extrahepatic PSC" | 148 148 trials 68 / 66 / 51 / 10 💬 | 118 118 drugs [ 39 39 drugs ] | 18 18 genes 141 pathways | 1022 (1) About 400 patients (2) 1,022 patients Age distribution💬 |
95 | Autoimmune hepatitis [Gast] 💬 | 52 52 trials 11 / 25 / 11 / 11 💬 | 68 68 drugs [ 27 27 drugs ] | 18 18 genes 111 pathways | 6884 (1) About 10,000 patients (2) 6,884 patients Age distribution💬 |
96 | Crohn disease [Gast] 💬 "Terminal ileitis" | 2,442 2,442 trials 898 / 766 / 1004 / 332 💬 | 1,278 1,278 drugs [ 248 248 drugs ] | 142 142 genes 209 pathways | 48320 (1) 36,418 patients (2) 48,320 patients Age distribution💬 |
97 | Ulcerative colitis [Gast] 💬 | 2,630 2,630 trials 943 / 957 / 1089 / 298 💬 | 1,459 1,459 drugs [ 265 265 drugs ] | 144 144 genes 202 pathways | 138079 (1) 143,733 patients (2) 138,079 patients Age distribution💬 |
98 | Eosinophilic gastrointestinal disease [Gast] 💬 "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "Neonatal Food-protein induced enterocolitis syndrome", "N-FPIES" | 172 172 trials 48 / 64 / 90 / 13 💬 | 149 149 drugs [ 39 39 drugs ] | 38 38 genes 135 pathways | 1184 (1) About 5,000 patients (By the research group) (2) 1,184 patients Age distribution💬 |
99 | Chronic intestinal pseudo-obstruction [Gast] 💬 "Chronic idiopathic pseudo-bowel obstruction", "Chronic Idiopathic Intestinal Pseudo-Obstruction", "CIIP" | 4 4 trials 0 / 4 / 0 / 0 💬 | 9 9 drugs [ 2 2 drugs ] | 1 1 gene 4 pathways | 186 (1) Child case: 100 patients, Adult case: 1,300 patients (2) 186 patients Age distribution💬 |
100 | Megacystis microcolon intestinal hypoperistalsis syndrome [Gast] 💬 "MMIHS", "Huge bladder short and small colon intestinal peristalsis deficiency" | 0 - | 0 - | 0 - | 1 (1) Less than 100 patients (By the research group) (2) 1 patient Age distribution💬 |
101 | Congenital isolated hypoganglionosis [Gast] 💬 "Intestinal ganglion cells insignificant disease" | 0 - | 0 - | 0 - | 17 (1) About 100 patients (By the research group) (2) 17 patients Age distribution💬 |
102 | Rubinstein-Taybi syndrome [Chr] 💬 "RSTS", "Histone acetylation disorder" | 3 3 trials 0 / 2 / 0 / 0 💬 | 5 5 drugs [ 1 1 drug ] | 7 7 genes 17 pathways | 7 (1) About 200 patients (By the research group) (2) 7 patients Age distribution💬 |
103 | Cardio-facio-cutaneous syndrome [Chr] 💬 "CFC syndrome" | 0 - | 0 - | 0 - | 7 (1) About 200 patients (By the research group) (2) 7 patients Age distribution💬 |
104 | Costello syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 10 (1) About 100 patients (By the research group) (2) 10 patients Age distribution💬 |
105 | CHARGE syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 25 (1) About 5,000 patients (By the research group) (2) 25 patients Age distribution💬 |
106 | Cryopyrin-associated periodic syndrome [Imm] 💬 "Cryopyrin associated periodic fever syndrome", "Familial cold autoinflammatory syndrome", "FCAS", "Mucke-Wells syndrome", "MWS", "Chronic infantile neurologic cutaneous, and articular syndrome", "CINCA syndrome", "Neonatal onset multisystem inflammatory disease", "NOMID" | 42 42 trials 29 / 14 / 13 / 5 💬 | 24 24 drugs [ 4 4 drugs ] | 4 4 genes 48 pathways | 83 (1) About 100 patients (By the research group) (2) 83 patients Age distribution💬 |
107 | Juvenile idiopathic arthritis [Imm] 💬 "JIA", "Systemic juvenile idiopathic arthritis", "Systemic-onset juvenile idiopathic arthritis", "sJIA", "Joint-type juvenile idiopathic arthritis", "Joint-type JIA" | 447 447 trials 181 / 82 / 206 / 69 💬 | 297 297 drugs [ 57 57 drugs ] | 52 52 genes 146 pathways | 918 (1) About 8,000 patients (2) 918 patients Age distribution💬 |
108 | TNF receptor-associated periodic syndrome [Imm] 💬 | 4 4 trials 5 / 1 / 2 / 1 💬 | 7 7 drugs [ 1 1 drug ] | 1 1 gene 44 pathways | 33 (1) Less than 100 patients (By the research group) (2) 33 patients Age distribution💬 |
109 | Atypical hemolytic uremic syndrome [Kid] 💬 "aHUS" | 114 114 trials 75 / 41 / 54 / 18 💬 | 36 36 drugs [ 7 7 drugs ] | 3 3 genes 11 pathways | 78 (1) Less than 200 patients (By the research group) (2) 78 patients Age distribution💬 |
110 | Blau syndrome [Imm] 💬 "Early-onset sarcoidosis", "Systemic granulomatous diseases", "Systemic inflammatory granulomatous disease", "Juvenile onset sarcoidosis", "Early-onset childhood sarcoidosis", "Childhood sarcoidosis", "Early onset sarcoidosis", "EOS" | 0 - | 0 - | 0 - | 22 (1) Less than 100 patients (By the research group) (2) 22 patients Age distribution💬 |
111 | Congenital myopathy [Neu] 💬 "Nemaline myopathy", "Central core disease", "Minicore myopathy", "Multi-minicore myopathy", "Myotubular myopathy", "X-linked myotubular myopathy", "XLMTM", "Centronuclear myopathy", "CNM", "Congenital fiber-type disproportion myopathy" | 10 10 trials 11 / 8 / 1 / 2 💬 | 17 17 drugs [ 5 5 drugs ] | 1 1 gene 9 pathways | 351 (1) About 1,000 patients (2) 351 patients Age distribution💬 |
112 | Marinesco-Sjogren syndrome [Neu] 💬 "Hereditary cerebellar ataxia-childhood cataracts" | 0 - | 0 - | 0 - | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
113 | Muscular dystrophy [Neu] 💬 "Dystrophinopathies", "Duchenne muscular dystrophy", "DMD", "Becker muscular dystrophy", "Limb-girdle muscular dystrophy", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "Limb gridle muscular dystrophy 1C", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "Congenital muscular dystrophy", "Facioscapulohumeral muscular dystrophy", "Emery-Dreifuss muscular dystrophy", "Oculopharyngeal muscular dystrophy", "Fukuyama-type congenital muscular dystrophy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "CIntegrin α7 deficient ongenital muscular dystrophy", "Merosin-deficient congenital muscular dystrophy", "Ullrich congenital muscular dystrophy", "Rigid spine syndrome", "Dynamin 2 deficient congenital muscular dystrophy", "Telesonin-deficient congenital muscular dystrophy", "Congenital muscular dystrophy with mitochondrial structural abnormalities" | 646 646 trials 401 / 281 / 275 / 65 💬 | 471 471 drugs [ 105 105 drugs ] | 59 59 genes 170 pathways | 5246 (1) About 25,400 patients (2) 5,246 patients Age distribution💬 |
114 | Non-dystrophic myotonia syndrome [Neu] 💬 "Non-dystrophic Myotonia", "Myotonia congenita", "Thomsen disease", "Autosomal-dominant myotonia congenita", "Becker disease", "Autosomal-recessive myotonia congenita", "Paramyotonia congenita", "Sodium channel myotonia" | 13 13 trials 1 / 3 / 5 / 0 💬 | 19 19 drugs [ 5 5 drugs ] | 18 18 genes 10 pathways | 23 (1) About 1,000 patients (2) 23 patients Age distribution💬 |
115 | Hereditary periodic paralysis [Neu] 💬 "Hereditary Hypokalemic Periodic Paralysis", "Andersen-Tawil syndrome", "Hereditary Hyperkalemic Periodic Paralysis" | 1 1 trial 1 / 0 / 0 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 13 13 genes 7 pathways | 60 (1) About 1,000 patients (2) 60 patients Age distribution💬 |
116 | Atopic myelitis [Neu] 💬 "Idiopathic eosinophilic myelitis" | 0 - | 0 - | 0 - | 47 (1) About 1,000 patients (2) 47 patients Age distribution💬 |
117 | Syringomyelia [Neu] 💬 "Symptomatic syringomyelia", "Asymptomatic syringomyelia", "Syringomyelia with Chiari I malformation", "Syringomyelia with Chiari II malformation", "Syringomyelia without Chiari malformation", "Secondary syringomyelia", "Idiopathic syringomyelia" | 3 3 trials 0 / 2 / 0 / 0 💬 | 5 5 drugs [ 1 1 drug ] | 0 - | 602 (1) About 3,000 patients (2) 602 patients Age distribution💬 |
118 | Myelomeningocele [Neu] 💬 "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele" | 5 5 trials 1 / 1 / 0 / 1 💬 | 7 7 drugs [ 4 4 drugs ] | 2 2 genes 10 pathways | 124 (1) 5.0~6.0 cases occur per 10,000 born (500~600 child patients are born per year) (2) 124 patients Age distribution💬 |
119 | Isaacs syndrome [Neu] 💬 "Morvan syndrome", "Morvan fibrillary chorea", "Anti-VGKC antibody-associated limbic encephalitis" | 0 - | 0 - | 0 - | 108 (1) About 100 patients (2) 108 patients Age distribution💬 |
120 | Hereditary dystonia [Neu] 💬 "DYT1 dystonia", "DYT2 dystonia", "DYT3 dystonia", "X-linked dystonia-parkinsonism", "Lubag", "DYT4 dystonia", "DYT5 dystonia", "DYT5a dystonia", "DYT5b dystonia", "DYT14 dystonia", "Segawa syndrome", "SS", "Dopa-responsive dystonia", "DRD", "DYT6 dystonia", "DYT7 dystonia", "DYT8 dystonia", "Paroxysmal nonkinesigenic dyskinesia 1", "PNKD1", "DYT9 dystonia", "Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity", "Paroxysmal choreoathetosis and episodic ataxia and spasticity", "CSE", "DYT10 dystonia", "Episodic kinesigenic dyskinesia 1", "EKD1", "DYT11 dystonia", "Myoclonus-dystonia syndrome", "MDS", "DYT12 dystonia", "Rapid-onset dystonia-parkinsonism", "RDP", "Alternating hemiplegia of childhood", "AHC", "Cerebellar ataxia, areflexia, pes cavus, optic atropy, and sensorineural hearing loss", "CAPOS", "DYT13 dystonia", "DYT15 dystonia", "DYT16 dystonia", "DYT17 dystonia", "DYT18 dystonia", "Paroxysmal execise-induced dyskinesia", "PED", "DYT19 dystonia", "Episodic kinesigenic dyskinesia 2", "EKD2", "DYT20 dystonia", "Paroxysmal nonkinesigenic dyskinesia 2", "PNKD2", "Neurodegeneration with Brain Iron Accumulation 1", "Pantothenate kinase-associated neurodegeneration", "PKAN", "Classical PKAN", "Atypical PKAN", "NBIA1", "Hallervorden-Spatz syndrome", "Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, pallidal degeneration", "Neurodegeneration with Brain Iron Accumulation 2", "Infantile neuroaxonal dystrophy", "INAD", "Classical INAD", "Atypical INAD", "NBIA2", "Karak syndrome", "Neurodegeneration with Brain Iron Accumulation 3", "Neuroferritinopathy", "NBIA3", "Neurodegeneration with Brain Iron Accumulation 4", "Aceruloplasminemia", "Hereditary ceruloplasmin deficiency", "NBIA4", "Neurodegeneration with Brain Iron Accumulation 5", "NBIA5", "Beta-propeller protein-associated neurodegeneration", "BPAN", "Fatty Acid Hydroxylase-associated neurodegeneration", "FAHN", "Dysmyelinating leukodystrophy and spastic paraparasis with or without dystonia, spastic paraplegia 35" | 26 26 trials 11 / 3 / 18 / 3 💬 | 19 19 drugs [ 3 3 drugs ] | 2 2 genes 2 pathways | 113 (1) About 500 patients (2) 113 patients Age distribution💬 |
121 | Neuroferritinopathy [Neu] 💬 | 0 - | 0 - | 0 - | 2 (1) Less than 100 patients (2) 2 patients Age distribution💬 |
122 | Superficial siderosis [Neu] 💬 "SS", "Classical superficial siderosis", "Classical SS", "Brain table hemosiderosis" | 3 3 trials 0 / 0 / 0 / 0 💬 | 3 3 drugs [ 2 2 drugs ] | 0 - | 198 (1) Less than 100 patients (2) 198 patients Age distribution💬 |
123 | Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy [Neu] 💬 "CARASIL", "Cerebral autosomal recessive arteriopathy with baldness and degenerative spondylosis", "Autosomal recessive leukoencephalopathy with baldness and degenerative spondylosis", "Cerebral autosomal recessive arteriopathy", "Autosomal recessive leukoencephalopathy" | 0 - | 0 - | 0 - | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
124 | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [Neu] 💬 "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease" | 12 12 trials 10 / 7 / 2 / 2 💬 | 14 14 drugs [ 5 5 drugs ] | 3 3 genes 11 pathways | 187 (1) About 200 patients (2) 187 patients Age distribution💬 |
125 | Hereditary diffuse leukoencephalopathy with spheroid [Neu] 💬 "HDLS", "Hereditary diffuse leukoencephalopathy" | 1 1 trial 0 / 1 / 0 / 0 💬 | 9 9 drugs [ 1 1 drug ] | 0 - | 65 (1) Less than 100 patients (2) 65 patients Age distribution💬 |
126 | Perry syndrome [Neu] 💬 | 0 - | 0 - | 0 - | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
127 | Frontotemporal lobar degeneration [Neu] 💬 "Frontotemporal dementia", "Semantic dementia" | 90 90 trials 32 / 36 / 31 / 8 💬 | 87 87 drugs [ 30 30 drugs ] | 39 39 genes 88 pathways | 1311 (1) About 12,000 patients (2) 1,311 patients Age distribution💬 |
128 | Bickerstaff brainstem encephalitis [Neu] 💬 | 0 - | 0 - | 0 - | 77 (1) Occurrence: About 100 patients per year (2) 77 patients Age distribution💬 |
129 | Acute encephalopathy with biphasic seizures and late reduced diffusion [Neu] 💬 "Epilepticus type biphasic acute encphalopathy", "Epilepticus type acute encphalopathy" | 1 1 trial 0 / 1 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 0 - | 46 (1) About 2,000~7,800 patients (Morbidity rate: 100~200 patients per year) (2) 46 patients Age distribution💬 |
130 | Congenital insensitivity to pain with anhydrosis [Neu] 💬 "CIPA", "Hereditary sensory and autonomic neuropathy type IV", "HSAN4", "Hereditary sensory and autonomic neuropathy type V", "HSAN5" | 0 - | 0 - | 0 - | 42 (1) About 200~300 patients (2) 42 patients Age distribution💬 |
131 | Alexander disease [Neu] 💬 "ALXDRD", "AxD", "Alexander Disease type 1", "ALXDRD1", "AxD1", "Alexander Disease type 2", "ALXDRD2", "AxD2", "Alexander disease type 3", "ALXDRD3", "AxD3" | 4 4 trials 3 / 3 / 4 / 0 💬 | 4 4 drugs [ 1 1 drug ] | 0 - | 46 (1) Less than 100 patients (2) 46 patients Age distribution💬 |
132 | Congenital supranuclear bulbar palsy [Neu] 💬 "Congenital suprabulbar paresis", "Worcester drought syndrome", "Worster-Drought syndrome" | 0 - | 0 - | 0 - | 8 (1) About 100 patients (2) 8 patients Age distribution💬 |
133 | Moebius syndrome [Neu] 💬 "Mobius syndrome", "Möbius syndrome" | 0 - | 0 - | 0 - | 13 (1) About 1,000 patients (2) 13 patients Age distribution💬 |
134 | Septo-optic dysplasia [Eye] 💬 "De Morsier syndrome" | 1 1 trial 0 / 0 / 0 / 1 💬 | 1 1 drug [ 0 - ] | 0 - | 13 (1) About 500 patients (2) 13 patients Age distribution💬 |
135 | Aicardi syndrome [Neu] 💬 | 1 1 trial 0 / 1 / 0 / 0 💬 | 9 9 drugs [ 3 3 drugs ] | 0 - | 15 (1) Less than 100 patients (2) 15 patients Age distribution💬 |
136 | Hemimegalencephaly [Neu] 💬 "Unilateral megalencephaly" | 0 - | 0 - | 0 - | 24 (1) Less than 100 patients (2) 24 patients Age distribution💬 |
137 | Focal cortical dysplasia [Neu] 💬 "FCD", "FCD type 1a", "FCD type 1b", "FCD type 1c", "FCD type 2a", "FCD type 2b", "FCD type 3a", "FCD type 3b", "FCD type 3c", "FCD type 3d" | 9 9 trials 0 / 6 / 0 / 0 💬 | 5 5 drugs [ 3 3 drugs ] | 1 1 gene 51 pathways | 72 (1) A few thousand patients (2) 72 patients Age distribution💬 |
138 | Nerve cell migration disorder [Neu] 💬 "Lissencephaly", "Neuronal migration defect", "Classical lissencephaly", "Ectopic gray matter", "Subcortical ectopic gray matter", "Periventricular nodular ectopic gray matter", "Polymicrogyria", "Cortical dysplasia with cobblestone appearance", "Schizencephaly", "Porencephaly", "Miller-Dieker syndrome", "Perisylvian polymicrogyria", "X-linked Lissencephaly" | 1 1 trial 0 / 1 / 0 / 0 💬 | 2 2 drugs [ 1 1 drug ] | 1 1 gene 106 pathways | 60 (1) About 1,000 patients (2) 60 patients Age distribution💬 |
139 | Congenital cerebral hypomyelination [Neu] 💬 "Congenital cerebral white matter aplasia", "Pelizaeus-Merzbacher disease", "Pelizaeus-Merzbacher-like disease 1", "Pelizaeus-Merzbacher-like disease type 1", "Hypomyelination with atrophy of the basal ganglia and cerebellum", "18q-syndrome", "Chromosome 18q deletion syndrome", "Allan-Herndon-Dudley syndrome", "Mitochondrial Hsp60 chaperonopathy", "Salla disease", "Free sialic acid storage disease", "Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum", "Hypomyelination and congenital cataract", "Ataxia, delayed dentition, and hypomyelination", "Peripheral demyelinating neuropathy", "Central dysmyelinating leukodystrophy", "Waardenburg syndrome", "Hirschsprung disease" | 10 10 trials 1 / 7 / 0 / 0 💬 | 7 7 drugs [ 2 2 drugs ] | 2 2 genes 2 pathways | 38 (1) About 200 patients (2) 38 patients Age distribution💬 |
140 | Dorabe syndrome [Neu] 💬 "Dravet syndrome" | 116 116 trials 46 / 25 / 80 / 11 💬 | 65 65 drugs [ 17 17 drugs ] | 50 50 genes 64 pathways | 67 (1) About 3,000 patients (2) 67 patients Age distribution💬 |
141 | Mesial temporal lobe epilepsy with hippocampal sclerosis [Neu] 💬 "Medial temporal lobe epilepsy with hippocampal sclerosis", "Mesial temporal lobe epilepsy with bilateral hippocampal sclerosis", "Medial temporal lobe epilepsy" | 1 1 trial 1 / 1 / 0 / 0 💬 | 1 1 drug [ 0 - ] | 0 - | 73 (1) About 5,000 patients (2) 73 patients Age distribution💬 |
142 | Myoclonic absence epilepsy [Neu] 💬 | 0 - | 0 - | 0 - | 4 (1) Less than 100 patients (2) 4 patients Age distribution💬 |
143 | Epilepsy with myoclonic-atonic seizure [Neu] 💬 "Epilepsy with myoclonic cataplexy" | 0 - | 0 - | 0 - | 22 (1) Less than 100 patients (2) 22 patients Age distribution💬 |
144 | Lennox-Gastaut syndrome [Neu] 💬 | 111 111 trials 35 / 17 / 79 / 8 💬 | 72 72 drugs [ 14 14 drugs ] | 49 49 genes 61 pathways | 282 (1) [Disease ID 144-148 total] About 4,300 patients (2) 282 patients Age distribution💬 |
145 | West syndrome [Neu] 💬 "Infantile spasm" | 43 43 trials 16 / 15 / 18 / 9 💬 | 52 52 drugs [ 15 15 drugs ] | 28 28 genes 26 pathways | 229 (1) [Disease ID 144-148 total] About 4,300 patients (2) 229 patients Age distribution💬 |
146 | Ohtahara syndrome [Neu] 💬 "Early infantile epileptic encephalopathy with suppression burst" | 0 - | 0 - | 0 - | 20 (1) [Disease ID 144-148 total] About 4,300 patients (2) 20 patients Age distribution💬 |
147 | Early myoclonic encephalopathy [Neu] 💬 | 0 - | 0 - | 0 - | 10 (1) [Disease ID 144-148 total] About 4,300 patients (2) 10 patients Age distribution💬 |
148 | Epilepsy of infancy with migrating focal seizure [Neu] 💬 "Infant epilepsy with migratory focus seizure", "Migrating partial seizures in infancy", "Infant epilepsy" | 0 - | 0 - | 0 - | 21 (1) [Disease ID 144-148 total] About 4,300 patients (2) 21 patients Age distribution💬 |
149 | Hemiconvulsion hemiplegia epilepsy syndrome [Neu] 💬 "One side convulsions", "Hemiplegia", "Epilepsy syndrome" | 25 25 trials 3 / 4 / 8 / 3 💬 | 35 35 drugs [ 13 13 drugs ] | 16 16 genes 22 pathways | 33 (1) Less than 100 patients (2) 33 patients Age distribution💬 |
150 | Ring chromosome 20 epilepsy syndrome [Neu] 💬 "Ring chromosome 20 syndrome" | 0 - | 0 - | 0 - | 15 (1) Less than 100 patients (2) 15 patients Age distribution💬 |
151 | Rasmussen encephalitis [Neu] 💬 | 1 1 trial 0 / 1 / 1 / 0 💬 | 2 2 drugs [ 1 1 drug ] | 5 5 genes 33 pathways | 46 (1) Less than 100 patients (2) 46 patients Age distribution💬 |
152 | PCDH19 related syndrome [Neu] 💬 "PCDH19 Epilepsy", "Epilepsy and mental retardation limited to females", "PCDH19 female pediatric epilepsy", "PCDH19-related epilepsy", "Protocadherin 19 (PCDH19)-related epilepsy" | 10 10 trials 5 / 5 / 5 / 1 💬 | 7 7 drugs [ 1 1 drug ] | 16 16 genes 7 pathways | 13 (1) Less than 100 patients (2) 13 patients Age distribution💬 |
153 | Acute encephalitis with refractory, repetitive partial seizure [Neu] 💬 repetitive partial seizure", "AERRPS", "Refractory frequent partial seizures intussusception acute encephalitis", "Febrile infection related epilepsy syndrome", "FIRES", "New onset refractory status epilepsy syndrome", "NORSE syndrome" | 0 - | 0 - | 0 - | 55 (1) About 100 patients (2) 55 patients Age distribution💬 |
154 | Epilepsy with continuous spikes and waves during slow sleep [Neu] 💬 "Epileptic encephalopathy with continuous spike-and-wave during sleep" | 7 7 trials 0 / 7 / 0 / 0 💬 | 4 4 drugs [ 3 3 drugs ] | 13 13 genes 7 pathways | 27 (1) [Disease ID 154-155 total] About 400 patients (2) 27 patients Age distribution💬 |
155 | Acquired aphasia with convulsive disorder [Neu] 💬 "Landau-Kleffner syndrome" | 1 1 trial 0 / 1 / 1 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 29 29 genes 14 pathways | 8 (1) [Disease ID 154-155 total] About 400 patients (2) 8 patients Age distribution💬 |
156 | Rett syndrome [Neu] 💬 "Typical Rett syndrome", "Atypical Rett syndrome" | 44 44 trials 4 / 24 / 16 / 0 💬 | 61 61 drugs [ 23 23 drugs ] | 57 57 genes 83 pathways | 98 (1) About 1,000 patients (2) 98 patients Age distribution💬 |
157 | Sturge-Weber syndrome [Neu] 💬 "Síndrome de Sturge-Weber" | 10 10 trials 3 / 6 / 1 / 1 💬 | 13 13 drugs [ 4 4 drugs ] | 5 5 genes 63 pathways | 77 (1) About 1,000 patients (2) 77 patients Age distribution💬 |
158 | Tuberous sclerosis [Neu] 💬 "Tuberous sclerosis complex" | 112 112 trials 49 / 40 / 55 / 17 💬 | 71 71 drugs [ 19 19 drugs ] | 35 35 genes 118 pathways | 925 (1) About 4,000~12,000 patients (2) 925 patients Age distribution💬 |
159 | Xeroderma pigmentosum [Neu] 💬 "XP", "XP-A", "XP-B", "XP-C", "XP-D", "XP-E", "XP-F", "XP-G", "XP-V" | 11 11 trials 1 / 8 / 1 / 0 💬 | 17 17 drugs [ 5 5 drugs ] | 5 5 genes 15 pathways | 86 (1) About 300~600 patients (2) 86 patients Age distribution💬 |
160 | Congenital ichthyosis [Skin] 💬 "Keratinopathic ichthyosis", "Epidermolytic ichthyosis", "Superficial epidermolytic ichthyosis", "Harlequin ichthyosis", "Autosomal recessive congenital ichthyosis", "Congenital Ichthyosiform Erythroderma", "Foliate ichthyosis", "Ichthyosis syndrome", "Netherton syndrome", "Sjogren-Larsson syndrome", "Sjögren-Larsson syndrome", "Keratitis-ichtyosis-deafness syndrome", "Dorfman-Chanarin syndrome", "Neutral lipid storage disease", "NLSD", "Multiple sulfatase deficiency", "Austin disease", "Recessive X-linked ichthyosis", "RXLI", "X-linked recessive ichthyosis", "Ichthyosis, brittle hair, impaired intelligence, decreased fertility and short stature", "IBID", "Trichothiodystrophy", "Follicular ichthyosis", "Congenital hemidysplasia, ichthyosiform erythroderma or nevus, and limb defects syndrome", "CHILD syndrome", "Conradi-Hunermann-Happle syndrome", "Conradi-Hünermann-Happle syndrome", "CHHS" | 42 42 trials 25 / 21 / 11 / 5 💬 | 71 71 drugs [ 21 21 drugs ] | 18 18 genes 112 pathways | 90 (1) About 200 patients (2) 90 patients Age distribution💬 |
161 | Familial benign chronic pemphigus [Skin] 💬 "Benign familial pemphigus", "Hailey-Hailey disease" | 5 5 trials 2 / 2 / 0 / 0 💬 | 9 9 drugs [ 4 4 drugs ] | 2 2 genes 24 pathways | 57 (1) About 300 patients (2) 57 patients Age distribution💬 |
162 | Pemphigoid [Skin] 💬 "Bullous pemphigoid", "BP", "Epidermolysis bullosa acquisita", "Mucous membrane pemphigoid", "MMP", "Cicatricial pemphigoid" | 90 90 trials 24 / 43 / 30 / 8 💬 | 122 122 drugs [ 47 47 drugs ] | 34 34 genes 144 pathways | 3764 (1) About 7,100 patients (Pemphigoid: About 6,850 patients、Epidermolysis bullosa acquisita: About 250 patients) (2) 3,764 patients Age distribution💬 |
163 | Idiopathic pure sudomotor failure [Skin] 💬 "Idiopathic acquired systemic anhidrosis", "Acquired idiopathic generalized anhidrosis", "AIGA", "Idiopathic segmental anhidrosis", "IPSF", "Sweat gland failure" | 0 - | 0 - | 0 - | 551 (1) About 100 patients~200 patients (2) 551 patients Age distribution💬 |
164 | Oculocutaneous albinism [Eye] 💬 "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Chédiak-Higashi syndrome", "Griscelli syndrome", "Non-syndromic oculocutaneous albinism" | 15 15 trials 3 / 9 / 1 / 0 💬 | 54 54 drugs [ 34 34 drugs ] | 35 35 genes 141 pathways | 28 (1) About 5,000 patients (2,800~11,200 patients) (2) 28 patients Age distribution💬 |
165 | Pachydermoperiostosis [Chr] 💬 "PDP", "Early type pachydermoperiostosis", "Early type PDP", "Incomplete type pachydermoperiostosis", "Incomplete type PDP", "Complete type pachydermoperiostosis", "Complete type PDP" | 0 - | 0 - | 0 - | 19 (1) Less than 100 patients (2) 19 patients Age distribution💬 |
166 | Pseudoxanthoma elasticum [Skin] 💬 "PXE" | 16 16 trials 3 / 13 / 2 / 1 💬 | 27 27 drugs [ 5 5 drugs ] | 5 5 genes 28 pathways | 109 (1) About 300 patients (2) 109 patients Age distribution💬 |
167 | Marfan syndrome [Skin] 💬 | 21 21 trials 15 / 6 / 12 / 4 💬 | 40 40 drugs [ 11 11 drugs ] | 10 10 genes 50 pathways | 1081 (1) About 15,000~20,000 patients (2) 1,081 patients Age distribution💬 |
168 | Ehlers-Danlos syndrome [Skin] 💬 "EDS", "Classic EDS", "Classical EDS", "cEDS", "Hypermobile Ehlers-Danlos syndrome", "Hypermobile EDS", "hEDS", "Classical-like Ehlers-Danlos syndrome", "Classical-like EDS", "clEDS", "Vascular Ehlers-Danlos syndrome", "Vascular EDS", "vEDS", "Kyphoscoliosis Ehlers-Danlos syndrome", "Kyphoscoliosis EDS", "kEDS", "Arthrochalasia Ehlers-Danlos syndrome", "Arthrochalasia EDS", "aEDS", "Dermatosparaxis Ehlers-Danlos syndrome", "Dermatosparaxis EDS", "dEDS", "D4ST1-deficient Ehlers-Danlos syndrome", "Dermatan 4-0-sulfotransferase 1-deficient EDS", "D4ST1-deficient EDS", "DDEDS" | 13 13 trials 1 / 2 / 5 / 3 💬 | 21 21 drugs [ 11 11 drugs ] | 11 11 genes 103 pathways | 179 (1) About 20,000 patients (2) 179 patients Age distribution💬 |
169 | Menkes disease [Met] 💬 | 6 6 trials 2 / 2 / 1 / 0 💬 | 6 6 drugs [ 4 4 drugs ] | 9 9 genes 14 pathways | 1 (1) Less than 100 patients (2) 1 patient Age distribution💬 |
170 | Occipital horn syndrome [Skin] 💬 | 2 2 trials 1 / 1 / 1 / 0 💬 | 4 4 drugs [ 3 3 drugs ] | 9 9 genes 14 pathways | 1 (1) Less than 100 patients (2) 1 patient Age distribution💬 |
171 | Wilson disease [Met] 💬 "WD" | 79 79 trials 42 / 24 / 32 / 15 💬 | 77 77 drugs [ 17 17 drugs ] | 6 6 genes 30 pathways | 715 (1) About 3,000 patients (2) 715 patients Age distribution💬 |
172 | Hypophosphatasia [Bone] 💬 | 34 34 trials 13 / 20 / 4 / 5 💬 | 17 17 drugs [ 4 4 drugs ] | 3 3 genes 6 pathways | 26 (1) About 100~200 patients (2) 26 patients Age distribution💬 |
173 | VATER syndrome [Chr] 💬 "VATER association", "VACTERL association" | 0 - | 0 - | 0 - | 15 (1) About 500 patients (2) 15 patients Age distribution💬 |
174 | Nasu-Hakola disease [Chr] 💬 "Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy", "PLOSL" | 0 - | 0 - | 0 - | 4 (1) About 200 patients (2) 4 patients Age distribution💬 |
175 | Weaver syndrome [Chr] 💬 | 0 - | 0 - | 0 - | (1) Less than 100 patients (2) - |
176 | Coffin-Lowry syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 5 (1) One patient per tens of thousand population (2) 5 patients Age distribution💬 |
177 | Joubert syndrome related disorder [Neu] 💬 "Joubert syndrome and related disorder", "Joubert syndrome", "JSRD", "Arima syndrome", "Senior-Loken syndrome", "Senior-Løken syndrome", "COACH syndrome", "Orofaciodigital syndrome" | 1 1 trial 0 / 0 / 0 / 0 💬 | 1 1 drug [ 0 - ] | 0 - | 11 (1) Less than 100 patients (2) 11 patients Age distribution💬 |
178 | Mowat-Wilson syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 13 (1) About 1,000 patients (2) 13 patients Age distribution💬 |
179 | Williams syndrome [Chr] 💬 | 5 5 trials 0 / 0 / 0 / 1 💬 | 14 14 drugs [ 7 7 drugs ] | 8 8 genes 32 pathways | 49 (1) Occurrence: One patient per twenty thousand population (2) 49 patients Age distribution💬 |
180 | ATR-X syndrome [Chr] 💬 "Alpha-thalassemia mental retardation syndrome" | 1 1 trial 0 / 1 / 0 / 0 💬 | 3 3 drugs [ 2 2 drugs ] | 0 - | 7 (1) Less than 100 patients (2) 7 patients Age distribution💬 |
181 | Crouzon syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 19 (1) [Disease ID 181-184 total] About 900 patients (2) 19 patients Age distribution💬 |
182 | Apert syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 6 (1) [Disease ID 181-184 total] About 900 patients (2) 6 patients Age distribution💬 |
183 | Pfeiffer syndrome [Chr] 💬 "Pfeiffer syndrome type 1", "Pfeiffer syndrome type 2", "Pfeiffer syndrome type 3" | 0 - | 0 - | 0 - | 6 (1) [Disease ID 181-184 total] About 900 patients (2) 6 patients Age distribution💬 |
184 | Antley-Bixler syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 3 (1) [Disease ID 181-184 total] About 900 patients (2) 3 patients Age distribution💬 |
185 | Coffin-Siris syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 4 (1) Less than 100 patients (2) 4 patients Age distribution💬 |
186 | Rothmund-Thomson syndrome [Chr] 💬 "RAPADILINO syndrome", "Baller-Gerold syndrome" | 0 - | 0 - | 0 - | 3 (1) Less than 100 patients (2) 3 patients Age distribution💬 |
187 | Kabuki syndrome [Chr] 💬 | 4 4 trials 1 / 0 / 0 / 0 💬 | 9 9 drugs [ 2 2 drugs ] | 2 2 genes 11 pathways | 14 (1) About 3,000~4,000 patients (2) 14 patients Age distribution💬 |
188 | Polysplenia syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 54 (1) [Disease ID 188-189 total] About 2,000 patients (2) 54 patients Age distribution💬 |
189 | Asplenia syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 84 (1) [Disease ID 188-189 total] About 2,000 patients (2) 84 patients Age distribution💬 |
190 | Branchio-oto-renal syndrome [Hear] 💬 "BOR syndrome" | 0 - | 0 - | 0 - | 8 (1) About 300 patients (2) 8 patients Age distribution💬 |
191 | Werner syndrome [Chr] 💬 | 3 3 trials 2 / 1 / 0 / 0 💬 | 4 4 drugs [ 3 3 drugs ] | 0 - | 102 (1) About 2,000 patients (2) 102 patients Age distribution💬 |
192 | Cockayne syndrome [Chr] 💬 "CS" | 4 4 trials 1 / 3 / 0 / 0 💬 | 7 7 drugs [ 3 3 drugs ] | 1 1 gene 51 pathways | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
193 | Prader-Willi syndrome [Chr] 💬 | 113 113 trials 27 / 42 / 50 / 13 💬 | 111 111 drugs [ 26 26 drugs ] | 48 48 genes 102 pathways | 172 (1) About 1,000 patients (2) 172 patients Age distribution💬 |
194 | Sotos syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 17 (1) About 2,500 patients (2) 17 patients Age distribution💬 |
195 | Noonan syndrome [Chr] 💬 | 25 25 trials 0 / 3 / 16 / 0 💬 | 23 23 drugs [ 5 5 drugs ] | 2 2 genes 9 pathways | 45 (1) About 600 patients (2) 45 patients Age distribution💬 |
196 | Young-Simpson syndrome [Chr] 💬 | 0 - | 0 - | 0 - | (1) About 100 patients (2) - |
197 | 1p36 deletion syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 8 (1) About 100 patients (2) 8 patients Age distribution💬 |
198 | 4p deletion syndrome [Chr] 💬 "4p-syndrome" | 0 - | 0 - | 0 - | 7 (1) Less than about 1,000 patients (2) 7 patients Age distribution💬 |
199 | 5p deletion syndrome [Chr] 💬 "5p-syndrome" | 0 - | 0 - | 0 - | 6 (1) Less than about 1,000 patients (One per fifty thousand born, probably less than 1,000 patients estimated) (2) 6 patients Age distribution💬 |
200 | Paternal uniparental disomy of chromosome 14 [Chr] 💬 "No. 14 chromosome father disomy syndrome", "Kagami-Ogata syndrome" | 0 - | 0 - | 0 - | 6 (1) Less than 100 patients (2) 6 patients Age distribution💬 |
201 | Angelman syndrome [Neu] 💬 | 25 25 trials 9 / 8 / 5 / 0 💬 | 40 40 drugs [ 11 11 drugs ] | 22 22 genes 20 pathways | 30 (1) 500~1,000 patients (2) 30 patients Age distribution💬 |
202 | Smith-Magenis syndrome [Chr] 💬 | 9 9 trials 7 / 4 / 2 / 1 💬 | 10 10 drugs [ 5 5 drugs ] | 4 4 genes 7 pathways | 1 (1) Less than 100 patients (2) 1 patient Age distribution💬 |
203 | 22q11.2 deletion syndrome [Chr] 💬 | 5 5 trials 2 / 1 / 1 / 0 💬 | 7 7 drugs [ 1 1 drug ] | 14 14 genes 23 pathways | 69 (1) About 4,500 patients (2) 69 patients Age distribution💬 |
204 | Emanuel syndrome [Chr] 💬 "Derivative 22 syndrome", "Partial trisomy (11", "22)" | 0 - | 0 - | 0 - | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
205 | Fragile X syndrome related disease [Chr] 💬 "Fragile X-associated tremor/ataxia syndrome", "FXTAS", "Fragile X-associated tremor", "Ataxia syndrome" | 5 5 trials 0 / 2 / 1 / 0 💬 | 7 7 drugs [ 5 5 drugs ] | 22 22 genes 25 pathways | 6 (1) [Disease ID 205-206 total] Less than 100 patients (2) 6 patients Age distribution💬 |
206 | Fragile X syndrome [Chr] 💬 | 108 108 trials 35 / 49 / 16 / 8 💬 | 91 91 drugs [ 36 36 drugs ] | 52 52 genes 77 pathways | 2 (1) [Disease ID 205-206 total] Less than 100 patients (2) 2 patients Age distribution💬 |
207 | Persistent truncus arteriosus [Card] 💬 "Persistent truncus arteriosus type I", "Persistent truncus arteriosus type II", "Persistent truncus arteriosus type III", "Persistent truncus arteriosus type IV" | 0 - | 0 - | 0 - | 32 (1) About 500 patients (2) 32 patients Age distribution💬 |
208 | Corrected transposition of great arteries [Card] 💬 | 0 - | 0 - | 0 - | 186 (1) [Disease ID 208-209 total] About 900 patients (2) 186 patients Age distribution💬 |
209 | Complete transposition of great vessel [Card] 💬 "Complete transposition of great arteries", "Complete TGA", "Complete transposition of great vessel type I", "Complete transposition of great arteries type I", "Complete TGA type I", "Complete transposition of great vessel type II", "Complete transposition of great arteries type II", "Complete TGA type II", "Complete transposition of great vessel type III", "Complete transposition of great arteries type III", "Complete TGA type III", "Complete transposition of great vessel type IV", "Complete transposition of great arteries type IV", "Complete TGA type IV" | 0 - | 0 - | 0 - | 244 (1) [Disease ID 208-209 total] About 900 patients (2) 244 patients Age distribution💬 |
210 | Single Ventricle [Card] 💬 "SV", "Single ventricle heart defect", "Univentricular heart", "UVH", "Single ventricular circulation syndrome" | 51 51 trials 23 / 15 / 24 / 6 💬 | 53 53 drugs [ 22 22 drugs ] | 32 32 genes 67 pathways | 425 (1) [Disease ID 210-213 total] About 3,500 patients (Patients of single ventricle heart defects) (2) 425 patients Age distribution💬 |
211 | Hypoplastic left heart syndrome [Card] 💬 "HLHS" | 22 22 trials 10 / 11 / 1 / 0 💬 | 29 29 drugs [ 9 9 drugs ] | 5 5 genes 14 pathways | 54 (1) [Disease ID 210-213 total] About 3,500 patients (Patients of single ventricle heart defects) (2) 54 patients Age distribution💬 |
212 | Tricuspid atresia [Card] 💬 "TA" | 5 5 trials 2 / 2 / 0 / 0 💬 | 6 6 drugs [ 6 6 drugs ] | 8 8 genes 12 pathways | 183 (1) [Disease ID 210-213 total] About 3,500 patients (Patients of single ventricle heart defects) (2) 183 patients Age distribution💬 |
213 | Pulmonary atresia without ventricular septum defect [Card] 💬 "Pulmonary atresia with intact ventricular septum", "Pulmonary atresia" | 0 - | 0 - | 0 - | 140 (1) [Disease ID 210-213 total] About 3,500 patients (Patients of single ventricle heart defects) (2) 140 patients Age distribution💬 |
214 | Pulmonary atresia with ventricular septum defect [Card] 💬 "PAVSD", "Pulmonary atresia with ventricular septal defect", "Pulmonary atresia", "Tetralogy of Fallot with pulmonary atresia", "TFPA" | 2 2 trials 0 / 0 / 0 / 0 💬 | 4 4 drugs [ 4 4 drugs ] | 0 - | 108 (1) [Disease ID 214-216 total] About 5,500 patients (Patients of tetralogy of Fallot related diseases) (2) 108 patients Age distribution💬 |
215 | Tetralogy of Fallot [Card] 💬 "Fallot tetralogy" | 18 18 trials 4 / 5 / 2 / 1 💬 | 26 26 drugs [ 14 14 drugs ] | 13 13 genes 45 pathways | 689 (1) [Disease ID 214-216 total] About 5,500 patients (Patients of tetralogy of Fallot related diseases) (2) 689 patients Age distribution💬 |
216 | Double outlet right ventricle [Card] 💬 | 0 - | 0 - | 0 - | 256 (1) [Disease ID 214-216 total] About 5,500 patients (Patients of tetralogy of Fallot related diseases) (2) 256 patients Age distribution💬 |
217 | Ebstein disease [Card] 💬 "Ebstein malformation" | 0 - | 0 - | 0 - | 130 (1) About 300 patients (2) 130 patients Age distribution💬 |
218 | Alport syndrome [Kid] 💬 "X chromosome-linked Alport syndrome", "Autosomal recessive Alport syndrome" | 30 30 trials 11 / 20 / 9 / 3 💬 | 36 36 drugs [ 15 15 drugs ] | 8 8 genes 46 pathways | 223 (1) About 1,200 patients (2) 223 patients Age distribution💬 |
219 | Galloway-Mowat syndrome [Kid] 💬 | 0 - | 0 - | 0 - | 1 (1) About 200 patients (2) 1 patient Age distribution💬 |
220 | Rapidly progressive glomerulonephritis [Kid] 💬 | 2 2 trials 0 / 1 / 2 / 0 💬 | 4 4 drugs [ 2 2 drugs ] | 1 1 gene 1 pathway | 1147 (1) About 3,800~5,800 patients in total estimated (2) 1,147 patients Age distribution💬 |
221 | Anti-glomerular basement membrane disease [Kid] 💬 | 1 1 trial 0 / 1 / 0 / 0 💬 | 3 3 drugs [ 1 1 drug ] | 0 - | 343 (1) About 200~400 patients (2) 343 patients Age distribution💬 |
222 | Primary nephrotic syndrome [Kid] 💬 "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN" | 310 310 trials 96 / 128 / 65 / 43 💬 | 295 295 drugs [ 117 117 drugs ] | 63 63 genes 194 pathways | 12221 (1) About 16,000 patients (2) 12,221 patients Age distribution💬 |
223 | Primary membranoproliferative glomerulonephritis [Kid] 💬 "Primary MPGN", "Primary membranoproliferative glomerulonephritis type I", "Primary MPGN I", "Primary membranoproliferative glomerulonephritis type III", "Primary MPGN III", "Mesangial proliferative primary membranoproliferative glomerulonephritis type I", "Mesangial proliferative primary MPGN I", "Primary membranoproliferative glomerulonephritis type I, chronic / nest-like type", "Primary MPGN I, chronic / nest-like type", "Primary membranoproliferative glomerulonephritis type I, acute / nest-like type", "Primary MPGN I, acute / nest-like type", "Primary membranoproliferative glomerulonephritis type I, chronic / diffuse type", "Primary MPGN I, chronic / diffuse type", "Primary membranoproliferative glomerulonephritis type I, non-lobed type", "Primary MPGN I, non-lobed type", "Primary membranoproliferative glomerulonephritis type I, acute / diffuse type", "Primary MPGN I, acute / diffuse type", "Primary membranoproliferative glomerulonephritis type I, intraductal proliferation type", "Primary MPGN I, intraductal proliferation type", "Primary membranoproliferative glomerulonephritis type I, lobation type", "Primary MPGN I, lobation type", "Primary membranoproliferative glomerulonephritis type I, end-of-life type", "Primary MPGN I, end-of-life type" | 0 - | 0 - | 0 - | 367 (1) About 1,000 patients (2) 367 patients Age distribution💬 |
224 | Purpura nephritis [Kid] 💬 | 16 16 trials 2 / 3 / 0 / 4 💬 | 43 43 drugs [ 21 21 drugs ] | 15 15 genes 58 pathways | 1023 (1) 400~640 cases / year (2) 1,023 patients Age distribution💬 |
225 | Congenital nephrogenic diabetes insipidus [Kid] 💬 "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus" | 15 15 trials 7 / 5 / 1 / 3 💬 | 48 48 drugs [ 18 18 drugs ] | 31 31 genes 65 pathways | 45 (1) About 200 patients (2) 45 patients Age distribution💬 |
226 | Interstitial cystitis with Hunners ulcer [Kid] 💬 "Interstitial cystitis" | 145 145 trials 48 / 58 / 27 / 17 💬 | 156 156 drugs [ 51 51 drugs ] | 64 64 genes 146 pathways | 885 (1) About 2,000 patients (2) 885 patients Age distribution💬 |
227 | Osler disease [Chr] 💬 "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease" | 56 56 trials 22 / 31 / 14 / 5 💬 | 72 72 drugs [ 21 21 drugs ] | 23 23 genes 136 pathways | 837 (1) About 10,000 patients (2) 837 patients Age distribution💬 |
228 | Bronchiolitis obliterans [Resp] 💬 "Obliterating bronchiolitis" | 97 97 trials 49 / 40 / 36 / 16 💬 | 118 118 drugs [ 32 32 drugs ] | 33 33 genes 156 pathways | 35 (1) About 300~500 patients (2) 35 patients Age distribution💬 |
229 | Autoimmune pulmonary alveolar proteinosis [Resp] 💬 "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP", "Autoimmune PAP", "Congenital PAP" | 44 44 trials 31 / 21 / 27 / 5 💬 | 22 22 drugs [ 7 7 drugs ] | 3 3 genes 14 pathways | 212 (1) About 900 patients (Autoimmune and congenital pulmonary alveolar proteinoses) (2) 212 patients Age distribution💬 |
230 | Alveolar hypoventilation syndrome [Resp] 💬 "AHS", "Hypoventilation syndrome", "Obesity hypoventilation syndrome", "OHS", "Congenital central hypoventilation syndrome", "CCHS", "Idiopathic central alveolar hypoventilation", "ICAH" | 6 6 trials 0 / 2 / 2 / 0 💬 | 7 7 drugs [ 4 4 drugs ] | 16 16 genes 26 pathways | 145 (1) About 3,000 patients (2) 145 patients Age distribution💬 |
231 | Alpha-1-antitrypsin deficiency [Resp] 💬 "AATD" | 93 93 trials 47 / 59 / 29 / 8 💬 | 77 77 drugs [ 8 8 drugs ] | 10 10 genes 36 pathways | 16 (1) Less than 100 patients (2) 16 patients Age distribution💬 |
232 | Carney complex [Chr] 💬 | 2 2 trials 0 / 1 / 0 / 0 💬 | 2 2 drugs [ 1 1 drug ] | 1 1 gene 29 pathways | 23 (1) Less than 100 patients (2) 23 patients Age distribution💬 |
233 | Wolfram syndrome [Endo] 💬 "Diabetes Insipidus, Diabetes mellitus, optic atrophy, and deafness syndrome", "DIDMOAD syndrome" | 11 11 trials 6 / 10 / 2 / 1 💬 | 17 17 drugs [ 8 8 drugs ] | 12 12 genes 41 pathways | 12 (1) About 200 patients (2) 12 patients Age distribution💬 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) [Met] 💬 "Peroxisomal disease", "Peroxisomal disorder", "Peroxisome biogenesis disorder", "PEX gene disorder", "Zellweger syndrome", "Neonatal adrenoleukodystrophy", "Infantile Refsum disease", "Rhizomelic chondrodysplasia punctata type 1", "RCDP type 1", "RCDP1", "Peroxisomal beta-oxidation enzyme deficiency", "Acyl-CoA oxidase deficiency", "AOX deficiency", "D-Bifunctional protein deficiency", "DBP deficiency", "Sterol carrier protein X deficiency", "SCPx deficiency", "2-methylacyl-CoA racemase deficiency", "Alpha-methylacyl-CoA racemase deficiency", "AMACR deficiency", "Plasmalogen biosynthesis enzyme deficiency", "Rhizomelic chondrodysplasia punctata type 2", "RCDP type 2", "RCDP2", "Rhizomelic chondrodysplasia punctata type 3", "RCDP type 3", "RCDP3", "Refsum disease", "Primary hyperoxaluria type 1", "PH1", "Acatalasemia", "Acatalasia", "Takahara disease", "Contiguous ABCD1/DXS1357E deletion syndrome", "CADDS" | 39 39 trials 30 / 21 / 18 / 5 💬 | 35 35 drugs [ 12 12 drugs ] | 13 13 genes 45 pathways | (1) Less than 100 patients (2) - |
235 | Hypoparathyroidism [Endo] 💬 "Accessory thyroid hypergasia disease" | 88 88 trials 16 / 20 / 38 / 18 💬 | 107 107 drugs [ 24 24 drugs ] | 5 5 genes 7 pathways | 302 (1) About 900 patients (2) 302 patients Age distribution💬 |
236 | Pseudohypoparathyroidism [Endo] 💬 "PHP", "PHP1a", "PHP1b", "PHP1c", "PHP2" | 3 3 trials 0 / 2 / 0 / 0 💬 | 3 3 drugs [ 2 2 drugs ] | 18 18 genes 23 pathways | 116 (1) About 400 patients (2) 116 patients Age distribution💬 |
237 | ACTH unresponsiveness [Endo] 💬 "Adrenocorticotropic hormone unresponsiveness", "Adrenocorticotropic hormone insensitivity", "Triple A syndrome", "Allgrove syndrome" | 0 - | 0 - | 0 - | 14 (1) Less than 100 patients (2) 14 patients Age distribution💬 |
238 | Vitamin D-resistant rickets [Bone] 💬 "VDRR", "Vitamin D-resistant osteomalacia", "VDRO", "FGF23-related hypophosphatemic disease", "FGF23-related hypophosphatemia", "Hypophosphatemic rickets/osteomalacia", "Hypophosphatemic rickets", "Hypophosphatemic osteomalacia", "Acquired vitamin D-resistant osteomalacia", "Acquired VDRO", "Tumor-induced osteomalacia", "TIO" | 28 28 trials 5 / 5 / 8 / 4 💬 | 20 20 drugs [ 9 9 drugs ] | 3 3 genes 16 pathways | 396 (1) 117 cases per year in Japan (95% CI 75-160) estimated by the national survey of the MHLW research group of abnormalities in hormonal signaling mechanisms (2) 396 patients Age distribution💬 |
239 | Vitamin D-dependent rickets [Endo] 💬 "Vitamin D-dependent osteomalacia", "VDDR", "Vitamin D-dependent rickets type 1", "VDDR1", "Vitamin D-dependent rickets type 2", "VDDR2" | 0 - | 0 - | 0 - | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
240 | Phenylketonuria [Met] 💬 "PKU", "Phenylalanine hydroxylase deficiency", "PAH deficiency", "Tetrahydrobiopterin deficiency", "BH4 deficiency", "BH4 reactive hyper pheemia" | 143 143 trials 79 / 31 / 43 / 26 💬 | 90 90 drugs [ 10 10 drugs ] | 1 1 gene 5 pathways | 264 (1) About 500 patients (2) 264 patients Age distribution💬 |
241 | Hypertyrosinemia type I [Met] 💬 "Tyrosinemia type I", "Tyrosinemia I", "Hereditary tyrosinemia, Type I", "Fumarylacetoacetate hydrolase deficiency", "FAH deficiency", "Acute hypertyrosinemia type I", "Acute tyrosinemia type I", "Acute tyrosinemia I", "Subacute hypertyrosinemia type I", "Subacute tyrosinemia type I", "Subacute tyrosinemia I", "Chronic hypertyrosinemia type I", "Chronic tyrosinemia type I", "Chronic tyrosinemia I" | 14 14 trials 4 / 1 / 1 / 1 💬 | 7 7 drugs [ 1 1 drug ] | 1 1 gene 5 pathways | 2 (1) [Disease ID 241-243 total] Less than 100 patients (2) 2 patients Age distribution💬 |
242 | Hypertyrosinemia type II [Met] 💬 "Tyrosinemia type II", "Tyrosinemia II", "Hereditary tyrosinemia, Type II", "Acute hypertyrosinemia type II", "Acute tyrosinemia type II", "Acute tyrosinemia II", "Subacute hypertyrosinemia type II", "Subacute tyrosinemia type II", "Subacute tyrosinemia II", "Chronic hypertyrosinemia type II", "Chronic tyrosinemia type II", "Chronic tyrosinemia II" | 0 - | 0 - | 0 - | (1) [Disease ID 241-243 total] Less than 100 patients (2) - |
243 | Hypertyrosinemia type III [Met] 💬 "Tyrosinemia type III", "Tyrosinemia III", "Hereditary tyrosinemia, Type III", "Acute hypertyrosinemia type III", "Acute tyrosinemia type III", "Acute tyrosinemia III", "Subacute hypertyrosinemia type III", "Subacute tyrosinemia type III", "Subacute tyrosinemia III", "Chronic hypertyrosinemia type III", "Chronic tyrosinemia type III", "Chronic tyrosinemia III" | 0 - | 0 - | 0 - | 1 (1) [Disease ID 241-243 total] Less than 100 patients (2) 1 patient Age distribution💬 |
244 | Maple syrup urine disease [Met] 💬 "MSUD" | 1 1 trial 0 / 1 / 1 / 0 💬 | 1 1 drug [ 1 1 drug ] | 0 - | 13 (1) About 100 patients (2) 13 patients Age distribution💬 |
245 | Propionic acidemia [Met] 💬 | 13 13 trials 5 / 7 / 1 / 0 💬 | 16 16 drugs [ 3 3 drugs ] | 1 1 gene 6 pathways | 15 (1) About 300 patients (2) 15 patients Age distribution💬 |
246 | Methylmalonic acidemia [Met] 💬 | 23 23 trials 13 / 15 / 2 / 2 💬 | 31 31 drugs [ 8 8 drugs ] | 17 17 genes 23 pathways | 30 (1) About 300 patients (2) 30 patients Age distribution💬 |
247 | Isovaleric acidemia [Met] 💬 "Isovaleric aciduria", "Isovaleric acid CoA dehydrogenase deficiency" | 0 - | 0 - | 0 - | 3 (1) Less than 100 patients (2) 3 patients Age distribution💬 |
248 | Glucose transporter type 1 deficiency [Met] 💬 "GLUT1 deficiency" | 29 29 trials 43 / 20 / 9 / 8 💬 | 9 9 drugs [ 1 1 drug ] | 0 - | 14 (1) Less than 100 patients (2) 14 patients Age distribution💬 |
249 | Glutaric acidemia type 1 [Met] 💬 | 0 - | 0 - | 0 - | 4 (1) Less than 100 patients (2) 4 patients Age distribution💬 |
250 | Glutaric acidemia type 2 [Met] 💬 "Multiple acyl-CoA dehydrogenase deficiency", "Multiple acyl-CoA dehydrogenation deficiency", "MADD", "Glutaric acidemia type 2, neonatal onset type", "Multiple acyl-CoA dehydrogenase deficiency, neonatal onset type", "Multiple acyl-CoA dehydrogenation deficiency, neonatal onset type", "MADD, neonatal onset type", "Glutaric acidemia type 2, infant/school child onset type", "Multiple acyl-CoA dehydrogenase deficiency, infant/school child onset type", "Multiple acyl-CoA dehydrogenation deficiency, infant/school child onset type", "MADD, infant/school child onset type", "Glutaric acidemia type 2, adult-onset type", "Multiple acyl-CoA dehydrogenase deficiency, adult-onset type", "Multiple acyl-CoA dehydrogenation deficiency, adult-onset type", "MADD, adult-onset type" | 0 - | 0 - | 0 - | 7 (1) Less than 100 patients (2) 7 patients Age distribution💬 |
251 | Urea cycle disorder [Met] 💬 "N-acetylglutamate synthase deficiency", "NAGS deficiency", "Carbamoyl phosphate synthetase I deficiency", "CPS1 deficiency", "Ornithine transcarbamylase deficiency", "OTC deficiency", "Classic citrullinemia", "Citrullinemia type I", "Argininosuccinic aciduria", "Argininemia", "Hiperornitinemia-hiperamonemia-homocitrulinuria syndrome", "HHH syndrome" | 54 54 trials 31 / 31 / 6 / 5 💬 | 61 61 drugs [ 15 15 drugs ] | 3 3 genes 28 pathways | 92 (1) OTC deficiency: About 500 patients; CPSI deficiency: About 100 patients; Argininosuccinic aciduria: About 100 patients; Other urea cycle disorders: Less than 100 patients; (2) 92 patients Age distribution💬 |
252 | Lysinuric protein intolerance [Met] 💬 | 0 - | 0 - | 0 - | 27 (1) Less than 100 patients (2) 27 patients Age distribution💬 |
253 | Congenital folate malabsorption [Met] 💬 "Hereditary folate malabsorption", "Folate malabsorption" | 0 - | 0 - | 0 - | (1) Less than 100 patients (2) - |
254 | Porphyria [Met] 💬 "Acute intermittent porphyria", "AIP", "Hereditary coproporphyria", "HCP", "Variegate porphyria", "VP", "Erythropoietic protoporphyria", "EPP", "Porphyria cutanea tarda", "PCT", "Congenital erythropoietic porphyria", "CEP", "X-linked dominant protoporphyria", "XLDP", "Hepatoerythropoietic porphyria", "HEP" | 72 72 trials 19 / 17 / 38 / 3 💬 | 53 53 drugs [ 16 16 drugs ] | 19 19 genes 35 pathways | 47 (1) About 200 patients (2) 47 patients Age distribution💬 |
255 | Multiple carboxylase deficiency [Met] 💬 "Holocarboxylase synthetase deficiency", "HCS deficiency", "Biotinidase deficiency" | 1 1 trial 1 / 1 / 0 / 0 💬 | 1 1 drug [ 0 - ] | 0 - | 6 (1) HCS deficiency: 1 / 1,000,000 occurrence in Japan; Biotinidase deficiency: a few cases reported; (2) 6 patients Age distribution💬 |
256 | Muscle glycogenosis [Met] 💬 "Muscular glycogenosis", "Muscle glycogen storage disease", "Muscular glycogen storage disease", "Glycogen storage disease type 0", "GSD0", "Glycogen synthase deficiency", "Glycogen storage disease type II", "GSDII", "Pompe disease", "Alpha-1,4-glucosidase acid deficiency", "Glycogen storage disease type III", "GSDIII", "Cori disease", "Forbes disease", "Glycogen debranching enzyme deficiency", "Glycogen storage disease type IV", "GSDIV", "Andersen disease", "Glycogen-branching enzyme deficiency", "GBED", "Glycogen storage disease type V", "GSDV", "McArdle disease", "Muscle phosphorylase deficiency", "Muscular phosphorylase deficiency", "Glycogen storage disease type VII", "GSDVII", "Tarui disease", "Phosphofructokinase deficiency", "PFK deficiency", "Glycogen storage disease type IXd", "GSDIXd", "Phosphorylase kinase deficiency", "Phosphoglycerate kinase deficiency", "PGK deficiency", "Glycogen storage disease type X", "GSDX", "Phosphoglycerate mutase deficiency", "Glycogen storage diseass type XI", "GSDXI", "Kanno disease", "Lactate dehydrogenase deficiency", "Glycogen storage diseass type XII", "GSDXII", "Aldolase A deficiency", "Glycogen storage diseass type XIII", "GSDXIII", "Beta-enolase deficiency", "Glycogen storage diseass type XIV", "GSDXIV", "Phosphoglucomutase deficiency", "Glycogen storage diseass type XV", "GSDXV", "Glycogenin 1 deficiency" | 180 180 trials 81 / 57 / 68 / 34 💬 | 133 133 drugs [ 29 29 drugs ] | 25 25 genes 105 pathways | 22 (1) About 3,000~6,000 patients estimated (2) 22 patients Age distribution💬 |
257 | Hepatic glycogenosis [Met] 💬 "Liver glycogenosis", "Hepatic glycogen storage disease", "Liver glycogen storage disease", "Glycogen storage disease type I", "GSDI", "von Gierke disease", "Glucose-6-phosphatase deficiency", "G6Pase deficiency", "Glycogen storage disease type III", "GSDIII", "Cori disease", "Forbes disease", "Glycogen debranching enzyme deficiency", "Glycogen storage disease type IV", "GSDIV", "Andersen disease", "Glycogen-branching enzyme deficiency", "GBED", "Adult polyglucosan body disease", "Glycogen storage disease type VI", "GSDVI", "Hers disease", "Hepatic phosphorylase deficiency", "Liver phosphorylase deficiency", "Glycogen storage disease type IX", "GSDIX", "Phosphorylase kinase deficiency" | 14 14 trials 4 / 7 / 0 / 0 💬 | 27 27 drugs [ 7 7 drugs ] | 3 3 genes 8 pathways | 101 (1) About 1,200 patients (2) 101 patients Age distribution💬 |
258 | Galactose-1-phosphate uridylyltransferase deficiency [Met] 💬 "Galactose-1-phosphate uridyltransferase deficiency", "Galactosemia type 1", "GALT deficiency" | 0 - | 0 - | 0 - | 2 (1) Less than 100 patients (2) 2 patients Age distribution💬 |
259 | Lecithin-cholesterol acyltransferase deficiency [Met] 💬 "LCAT deficiency", "Classical lecithin-cholesterol acyltransferase deficiency", "Classical LCAT deficiency", "Partial lecithin-cholesterol acyltransferase deficiency", "Partial LCAT deficiency", "Fish-eye disease" | 1 1 trial 0 / 0 / 0 / 0 💬 | 1 1 drug [ 0 - ] | 0 - | 4 (1) Less than 100 patients (2) 4 patients Age distribution💬 |
260 | Sitosterolemia [Met] 💬 | 12 12 trials 0 / 1 / 5 / 0 💬 | 11 11 drugs [ 3 3 drugs ] | 1 1 gene 1 pathway | 24 (1) Less than 100 patients (2) 24 patients Age distribution💬 |
261 | Tangier disease [Met] 💬 | 0 - | 0 - | 0 - | 9 (1) Less than 100 patients (2) 9 patients Age distribution💬 |
262 | Primary hyperchylomicronemia [Met] 💬 | 0 - | 0 - | 0 - | 46 (1) About 300 patients (2) 46 patients Age distribution💬 |
263 | Cerebrotendinous xanthomatosis [Met] 💬 "27-hydroxylase deficiency", "CYP27 deficiency" | 6 6 trials 0 / 1 / 2 / 0 💬 | 11 11 drugs [ 2 2 drugs ] | 2 2 genes 4 pathways | 48 (1) Less than 100 patients (2) 48 patients Age distribution💬 |
264 | Abetalipoproteinemia [Met] 💬 "Microsomal triglyceride transfer protein deficiency", "MTP deficiency" | 0 - | 0 - | 0 - | 4 (1) Less than 100 patients (Only a few pedigrees in Japan since the first report in 1,983) (2) 4 patients Age distribution💬 |
265 | Lipodystrophy [Met] 💬 "Generalized congenital lipodystrophy", "Berardinelli-Seip syndrome", "Familial partial lipodystrophy", "Dunnigan-type familial partial lipodystrophy", "Kobbering-type familial partial lipodystrophy", "Acquired generalized lipodystrophy", "Lawrence syndrome", "Partial acquired lipodystrophy", "Barraquer-Simons syndrome" | 112 112 trials 33 / 34 / 20 / 30 💬 | 155 155 drugs [ 55 55 drugs ] | 25 25 genes 97 pathways | 33 (1) About 100 patients (2) 33 patients Age distribution💬 |
266 | Familial mediterranean fever [Imm] 💬 | 28 28 trials 1 / 9 / 10 / 1 💬 | 22 22 drugs [ 5 5 drugs ] | 14 14 genes 59 pathways | 530 (1) About 300 patients (2) 530 patients Age distribution💬 |
267 | Hyper-IgD syndrome [Imm] 💬 "HIDS", "Mevalonate kinase deffiency", "Hyperimmunoglobulinemia D and periodic fever syndrome" | 11 11 trials 0 / 2 / 9 / 0 💬 | 6 6 drugs [ 1 1 drug ] | 1 1 gene 44 pathways | 2 (1) Less than 100 patients (2) 2 patients Age distribution💬 |
268 | Nakajo-Nishimura syndrome [Imm] 💬 "Autoinflammation, lipodystrophy, and dermatosis syndrome", "CANDLE syndrome", "JMP syndrome", "Nakajo syndrome" | 0 - | 0 - | 0 - | 7 (1) Less than 100 patients (2) 7 patients Age distribution💬 |
269 | Pyogenic arthritis [Imm] 💬 "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome" | 23 23 trials 7 / 14 / 7 / 2 💬 | 30 30 drugs [ 12 12 drugs ] | 15 15 genes 106 pathways | 7 (1) Less than 100 patients (2) 7 patients Age distribution💬 |
270 | Chronic recurrent multifocal osteomyelitis [Bone] 💬 | 1 1 trial 0 / 0 / 0 / 0 💬 | 10 10 drugs [ 9 9 drugs ] | 6 6 genes 73 pathways | 102 (1) Less than 100 patients (2) 102 patients Age distribution💬 |
271 | Ankylosing spondylitis [Bone] 💬 "Spondylarthritis ankylopoietica" | 574 574 trials 236 / 145 / 234 / 113 💬 | 359 359 drugs [ 68 68 drugs ] | 41 41 genes 146 pathways | 4552 (1) About 4,500 patients (2) 4,552 patients Age distribution💬 |
272 | Fibrodysplasia ossificans progressiva [Bone] 💬 "FOP" | 39 39 trials 17 / 26 / 15 / 3 💬 | 38 38 drugs [ 7 7 drugs ] | 27 27 genes 95 pathways | 25 (1) Less than 100 patients (2) 25 patients Age distribution💬 |
273 | Congenital scoliosis with rib anomaly [Bone] 💬 "Congenital scoliosis" | 0 - | 0 - | 0 - | 21 (1) Less than about 2,000 patients (Children under 11) (2) 21 patients Age distribution💬 |
274 | Osteogenesis Imperfecta [Bone] 💬 | 91 91 trials 24 / 23 / 32 / 11 💬 | 101 101 drugs [ 20 20 drugs ] | 11 11 genes 48 pathways | 121 (1) About 6,000 patients (2) 121 patients Age distribution💬 |
275 | Thanatophoric dysplasia [Bone] 💬 | 0 - | 0 - | 0 - | 5 (1) Less than 100 patients (2) 5 patients Age distribution💬 |
276 | Achondroplasia [Bone] 💬 | 51 51 trials 27 / 39 / 13 / 6 💬 | 34 34 drugs [ 6 6 drugs ] | 4 4 genes 26 pathways | 88 (1) 6,000 patients nationwide (estimated by frequency of occurrence) (2) 88 patients Age distribution💬 |
277 | Lymphangiomatosis [Resp] 💬 "Generalized lymphatic anomaly", "Gorham disease", "Gorham-Stout disease", "Diffuse lymphangiomatosis", "Mass osteolysis" | 6 6 trials 2 / 2 / 1 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 1 1 gene 51 pathways | 56 (1) About 100 patients (estimated by the national survey of the research group) (2) 56 patients Age distribution💬 |
278 | Huge lymphatic malformation with cervicofacial lesion [Resp] 💬 "Huge lymphatic malformation", "Lymphatic malformation" | 19 19 trials 12 / 10 / 4 / 4 💬 | 22 22 drugs [ 7 7 drugs ] | 5 5 genes 63 pathways | 17 (1) About 600 patients (2) 17 patients Age distribution💬 |
279 | Huge venous malformation with cervical, oral and pharyngeal diffuse lesion [Card] 💬 oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation" | 15 15 trials 1 / 7 / 1 / 2 💬 | 24 24 drugs [ 10 10 drugs ] | 3 3 genes 105 pathways | 47 (1) About 200 patients (2) 47 patients Age distribution💬 |
280 | Huge arteriovenous malformation with cervicofacial or limb lesion [Card] 💬 "Huge arteriovenous malformation", "Arteriovenous malformation" | 27 27 trials 14 / 7 / 2 / 6 💬 | 30 30 drugs [ 15 15 drugs ] | 14 14 genes 153 pathways | 104 (1) About 700 patients (2) 104 patients Age distribution💬 |
281 | Klippel-Trenaunay-Weber syndrome [Card] 💬 "Klippel-Trenauney-Weber syndrome", "Klippel-Trenaunay syndrome", "Klippel-Trenauney syndrome", "KTS", "Parkes Weber syndrome", "PWS" | 2 2 trials 0 / 0 / 0 / 0 💬 | 2 2 drugs [ 1 1 drug ] | 1 1 gene 51 pathways | 239 (1) About 3,000 patients (2) 239 patients Age distribution💬 |
282 | Congenital dyserythropoietic anemia [Hem] 💬 "CDA" | 1 1 trial 0 / 0 / 0 / 1 💬 | 1 1 drug [ 1 1 drug ] | 2 2 genes 4 pathways | 11 (1) Less than 100 patients (2) 11 patients Age distribution💬 |
283 | Acquired pure red cell aplasia [Hem] 💬 "Pure red cell aplasia" | 19 19 trials 7 / 13 / 2 / 5 💬 | 36 36 drugs [ 23 23 drugs ] | 20 20 genes 102 pathways | 829 (1) Incidence per year: 0.3 patients per one million population (2) 829 patients Age distribution💬 |
284 | Diamond-Blackfan anemia [Hem] 💬 | 36 36 trials 18 / 25 / 4 / 2 💬 | 95 95 drugs [ 34 34 drugs ] | 23 23 genes 126 pathways | 23 (1) About 200 patients (2) 23 patients Age distribution💬 |
285 | Fanconi anemia [Hem] 💬 | 62 62 trials 27 / 37 / 3 / 1 💬 | 93 93 drugs [ 30 30 drugs ] | 30 30 genes 144 pathways | 13 (1) About 200 patients (2) 13 patients Age distribution💬 |
286 | Hereditary sideroblastic anemia [Hem] 💬 "Congenital sideroblastic anemia", "Sideroblastic anemia" | 7 7 trials 5 / 2 / 1 / 1 💬 | 20 20 drugs [ 10 10 drugs ] | 8 8 genes 43 pathways | 13 (1) Less than 100 patients (2) 13 patients Age distribution💬 |
287 | Epstein syndrome [Chr] 💬 | 0 - | 0 - | 0 - | 12 (1) About 200 patients (2) 12 patients Age distribution💬 |
288 | Autoimmune acquired coagulation factor deficiency [Imm] 💬 "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "VWF deficiency", "von Willebrand Disease", "VWD", "Factor V deficiency", "Factor X deficiency" | 206 206 trials 44 / 31 / 95 / 28 💬 | 231 231 drugs [ 28 28 drugs ] | 10 10 genes 21 pathways | 414 (1) About 700 patients (2) 414 patients Age distribution💬 |
289 | Cronkhite-Canada syndrome [Gast] 💬 | 1 1 trial 0 / 0 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 0 - | 189 (1) About 500 patients (2) 189 patients Age distribution💬 |
290 | Chronic nonspecific multiple ulcers of the small intestine [Gast] 💬 "Nonspecific multiple ulcers in the small intestine" | 1 1 trial 1 / 1 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 1 1 gene 1 pathway | 88 (1) About 200 patients (2) 88 patients Age distribution💬 |
291 | Hirschsprung disease, entire colon type [Gast] 💬 entire colon type", "Hirschsprung disease, small intestine type", "Hirschsprung disease", "Hirschprung disease", "Hirschsprung disease associated entercolitis" | 12 12 trials 0 / 1 / 2 / 1 💬 | 24 24 drugs [ 15 15 drugs ] | 0 - | 19 (1) About 10,000 patients (Among them, entire colon type and small intestine type: About 1,000 patients) (2) 19 patients Age distribution💬 |
292 | Cloacal exstrophy [Gast] 💬 "Vesicointestinal fissure" | 0 - | 0 - | 0 - | 16 (1) About 300 patients (2) 16 patients Age distribution💬 |
293 | Persistent cloaca [Gast] 💬 | 0 - | 0 - | 0 - | 42 (1) About 600 patients (2) 42 patients Age distribution💬 |
294 | Congenital diaphragmatic hernia [Resp] 💬 | 16 16 trials 6 / 4 / 6 / 3 💬 | 26 26 drugs [ 5 5 drugs ] | 5 5 genes 14 pathways | 13 (1) About 5,000 patients (2) 13 patients Age distribution💬 |
295 | Infant huge hepatic hemangioma [Gast] 💬 "Infant giant liver hemangioma" | 0 - | 0 - | 0 - | (1) Less than 100 patients (2) - |
296 | Biliary atresia [Gast] 💬 | 71 71 trials 6 / 19 / 12 / 5 💬 | 70 70 drugs [ 39 39 drugs ] | 35 35 genes 60 pathways | 422 (1) About 3,500 patients (2) 422 patients Age distribution💬 |
297 | Alagille syndrome [Chr] 💬 | 45 45 trials 7 / 21 / 16 / 2 💬 | 21 21 drugs [ 10 10 drugs ] | 3 3 genes 5 pathways | 41 (1) About 200~300 patients (2) 41 patients Age distribution💬 |
298 | Hereditary pancreatitis [Gast] 💬 "Chronic pancreatitis" | 95 95 trials 23 / 25 / 17 / 7 💬 | 148 148 drugs [ 51 51 drugs ] | 53 53 genes 142 pathways | 31 (1) About 300~400 patients (2) 31 patients Age distribution💬 |
299 | Cystic fibrosis [Gast] 💬 | 1,695 1,695 trials 668 / 515 / 636 / 214 💬 | 1,527 1,527 drugs [ 268 268 drugs ] | 111 111 genes 174 pathways | 12 (1) Less than 100 patients (2) 12 patients Age distribution💬 |
300 | IgG4-related disease [Imm] 💬 "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease" | 40 40 trials 4 / 8 / 15 / 5 💬 | 47 47 drugs [ 21 21 drugs ] | 18 18 genes 141 pathways | 3371 (1) About 8,000 patients (2) 3,371 patients Age distribution💬 |
301 | Macular dystrophy [Eye] 💬 "Vitelliform macular dystrophy", "Best vitelliform macular dystrophy", "Best disease", "Stargardt disease", "Occult macular dystrophy", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy" | 46 46 trials 21 / 28 / 8 / 1 💬 | 42 42 drugs [ 11 11 drugs ] | 9 9 genes 67 pathways | 217 (1) 1,000 patients (2) 217 patients Age distribution💬 |
302 | Leber hereditary optic neuropathy [Eye] 💬 | 23 23 trials 29 / 12 / 15 / 6 💬 | 15 15 drugs [ 5 5 drugs ] | 5 5 genes 33 pathways | 126 (1) Estimated number of new occurrences per year: 117 patients (2) 126 patients Age distribution💬 |
303 | Usher syndrome [Eye] 💬 [Ear] 💬 | 10 10 trials 6 / 10 / 2 / 0 💬 | 11 11 drugs [ 0 - ] | 0 - | 20 (1) About 8,160 patients (2) 20 patients Age distribution💬 |
304 | Juvenile-onset bilateral sensorineural hearing loss [Ear] 💬 | 0 - | 0 - | 0 - | 42 (1) About 4,000 patients (2) 42 patients Age distribution💬 |
305 | Delayed endolymphatic hydrops [Ear] 💬 | 1 1 trial 0 / 0 / 0 / 0 💬 | 1 1 drug [ 1 1 drug ] | 0 - | 27 (1) About 4,000~5,000 patients (2) 27 patients Age distribution💬 |
306 | Eosinophilic sinusitis [Imm] 💬 [Ear] 💬 | 0 - | 0 - | 0 - | 17525 (1) About 20,000 patients (2) 17,525 patients Age distribution💬 |
307 | Canavan disease [Neu] 💬 | 6 6 trials 3 / 3 / 0 / 0 💬 | 11 11 drugs [ 5 5 drugs ] | 2 2 genes 2 pathways | 1 (1) A few patients (2) 1 patient Age distribution💬 |
308 | Progressive leukoencephalopathy [Neu] 💬 "Megalencephalic leukoencephalopathy with subcortical cyst", "Leukoencephalopathy with vanishing white matter", "Leukoencephalopathy, progressive, with ovarian failure" | 0 - | 0 - | 0 - | 20 (1) Less than 100 patients (2) 20 patients Age distribution💬 |
309 | Progressive myoclonus epilepsy [Neu] 💬 "Unverricht-Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME" | 11 11 trials 0 / 0 / 6 / 0 💬 | 15 15 drugs [ 2 2 drugs ] | 4 4 genes 9 pathways | 41 (1) About 3,000 patients (2) 41 patients Age distribution💬 |
310 | Congenital anomalies syndrome [Chr] 💬 "Partial trisomy 1q syndrome", "Trisomy 1q", "9q34 deletion syndrome", "Cornelia de Lange syndrome", "CdLS", "Smith-Lemli-Opitz syndrome", "SLO syndrome" | 11 11 trials 2 / 7 / 0 / 0 💬 | 20 20 drugs [ 10 10 drugs ] | 3 3 genes 7 pathways | 30 (1) About 4,000 patients (2) 30 patients Age distribution💬 |
311 | Congenital tricuspid stenosis [Card] 💬 | 0 - | 0 - | 0 - | 3 (1) About 500 patients (2) 3 patients Age distribution💬 |
312 | Congenital mitral stenosis [Card] 💬 | 0 - | 0 - | 0 - | 12 (1) About 100 patients (2) 12 patients Age distribution💬 |
313 | Congenital pulmonary vein stenosis [Card] 💬 | 0 - | 0 - | 0 - | 1 (1) About 80 patients (2) 1 patient Age distribution💬 |
314 | Vascular sling [Card] 💬 | 0 - | 0 - | 0 - | 2 (1) About 600 patients (2) 2 patients Age distribution💬 |
315 | Nail-Patella syndrome [Kid] 💬 "LMX1B-associated nephropathy" | 0 - | 0 - | 0 - | 7 (1) About 500 patients (2) 7 patients Age distribution💬 |
316 | Carnitine cycle disorder [Met] 💬 "Carnitine palmitoyltransferase I deficiency", "CPT1 deficiency", "Carnitine palmitoyltransferase II deficiency", "CPT2 deficiency", "Carnitine-acylcarnitine translocase deficiency", "CACT deficiency", "Carnitine transporter deficiency", "OCTN-2 deficiency" | 4 4 trials 0 / 1 / 1 / 0 💬 | 10 10 drugs [ 4 4 drugs ] | 2 2 genes 11 pathways | 19 (1) About 960 patients (2) 19 patients Age distribution💬 |
317 | Trifunctional protein deficiency [Met] 💬 "TFP deficiency", "Trifunctional protein deficiency, neonatal onset", "TFP deficiency, neonatal onset", "Trifunctional protein deficiency, infant onset", "TFP deficiency, infant onset", "Trifunctional protein deficiency, delayed onset", "TFP deficiency, delayed onset", "Trifunctional protein deficiency, pre onset", "TFP deficiency, pre onset" | 4 4 trials 1 / 0 / 0 / 0 💬 | 9 9 drugs [ 4 4 drugs ] | 1 1 gene 1 pathway | 4 (1) Less than 100 patients (2) 4 patients Age distribution💬 |
318 | Citrin deficiency [Met] 💬 "Neonatal intrahepatic cholestasis caused by citrin deficiency", "NICCD", "Adult-onset type II citrullinemia", "CTLN2" | 2 2 trials 0 / 1 / 0 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 0 - | 62 (1) About 1,500 patients (2) 62 patients Age distribution💬 |
319 | Sepiapterin reductase deficiency [Met] 💬 | 0 - | 0 - | 0 - | 2 (1) Less than 100 patients (About one patient) (2) 2 patients Age distribution💬 |
320 | Inherited glycosylphosphatidylinositol deficiency [Neu] 💬 "Inherited GPI deficiency", "IGD", "Congenital glycosylphosphatidylinositol deficiency", "Congenital GPI deficiency" | 3 3 trials 0 / 0 / 0 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 0 - | (1) Less than 100 patients (2) - |
321 | Non-ketotic hyperglycinemia [Met] 💬 "NKH", "Neonatal non-ketotic hyperglycinemia", "Neonatal NKH", "Infantile non-ketotic hyperglycinemia", "Infantile NKH" | 1 1 trial 0 / 0 / 0 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 0 - | 2 (1) Less than 100 patients (2) 2 patients Age distribution💬 |
322 | Beta-ketothiolase deficiency [Met] 💬 | 0 - | 0 - | 0 - | (1) Less than 100 patients (2) - |
323 | Aromatic L-amino acid decarboxylase deficiency [Met] 💬 | 0 - | 0 - | 0 - | 4 (1) Less than 100 patients (About 10 cases) (2) 4 patients Age distribution💬 |
324 | Methylglutaconic aciduria [Met] 💬 "3-methylglutaconyl-CoA hydratase deficiency", "3-methylglutaconic aciduria", "3-MGA", "3-MGA type I", "Barth syndrome", "3-MGA type II", "Costeff syndrome", "3-MGA type III", "Mitochondrial respiratory chain disorder", "3-MGA type IV", "Dilated cardiomyopathy with ataxia syndrome", "DCMA syndrome", "3-MGA type V" | 4 4 trials 5 / 2 / 2 / 1 💬 | 4 4 drugs [ 3 3 drugs ] | 1 1 gene 10 pathways | 1 (1) Less than 100 patients (2) 1 patient Age distribution💬 |
325 | Hereditary autoinflammatory syndrome [Imm] 💬 "NLRC4 abnormality", "Adenosine deaminase 2 deficiency", "ADA2 deficiency", "DADA2", "Aicardi-Goutieres syndrome", "AGS", "A20 haploinsufficiency", "HA20" | 5 5 trials 1 / 4 / 0 / 0 💬 | 11 11 drugs [ 6 6 drugs ] | 2 2 genes 35 pathways | 13 (1) Less than 100 patients (Adult patients reported in all cases) (2) 13 patients Age distribution💬 |
326 | Osteopetrosis [Met] 💬 "Neonatal / infantile osteopetrosis", "Intermediate osteopetrosis", "Delayed-onset osteopetrosis" | 18 18 trials 4 / 12 / 4 / 0 💬 | 43 43 drugs [ 14 14 drugs ] | 17 17 genes 82 pathways | 23 (1) About 100 patients (2) 23 patients Age distribution💬 |
327 | Idiopathic thrombosis [Hem] 💬 | 0 - | 0 - | 0 - | 205 (1) Based on the national survey of the research group, the total number of patients in Japan is estimated as about 2,000 patients. Occurrence per year in naonates and infants: Less than 100 patients, in adult: About 500 patients. (2) 205 patients Age distribution💬 |
328 | Anterior segment dysgenesis [Eye] 💬 "ASD" | 0 - | 0 - | 0 - | 13 (1) About 6,000 patients (2) 13 patients Age distribution💬 |
329 | Aniridia [Eye] 💬 | 3 3 trials 0 / 2 / 0 / 0 💬 | 2 2 drugs [ 2 2 drugs ] | 0 - | 120 (1) About 1,200 patients (2) 120 patients Age distribution💬 |
330 | Congenital tracheal stenosis [Resp] 💬 "Congenital subglottic stenosis" | 1 1 trial 0 / 1 / 0 / 0 💬 | 3 3 drugs [ 2 2 drugs ] | 0 - | 41 (1) About 1,000 patients (2) 41 patients Age distribution💬 |
331 | Idiopathic multicentric castleman disease [Hem] 💬 "iMCD", "Castleman disease" | 33 33 trials 15 / 24 / 2 / 4 💬 | 41 41 drugs [ 21 21 drugs ] | 22 22 genes 123 pathways | 1526 (1) About 1,500 patients (2) 1,526 patients Age distribution💬 |
332 | Gelatinous drop-like corneal dystrophy [Eye] 💬 | 0 - | 0 - | 0 - | 4 (1) About 400 patients (2) 4 patients Age distribution💬 |
333 | Hutchinson-Gilford syndrome [Chr] 💬 "Hutchinson-Gilford progeria syndrome", "HGPS" | 8 8 trials 2 / 5 / 0 / 0 💬 | 8 8 drugs [ 3 3 drugs ] | 4 4 genes 6 pathways | (1) Less than 100 patients (2) - |
334 | Cerebral creatine deficiency syndrome [Neu] 💬 "CCDS" | 0 - | 0 - | 0 - | (1) Less than 100 patients (2) - |
335 | Nephronophthisis [Kid] 💬 "NPHP", "NPH" | 1 1 trial 0 / 0 / 0 / 0 💬 | 1 1 drug [ 0 - ] | 0 - | 3 (1) About 130-220 patients (2) 3 patients Age distribution💬 |
336 | Familial hypobetalipoproteinemia 1 [Met] 💬 "FHBL1" | 0 - | 0 - | 0 - | (1) Several families only (2) - |
337 | Homocystinuria [Met] 💬 "Homocystinuria type I", "Cystathionine beta-synthase deficiency", "CBS deficiency", "Homocystinuria type II", "Homocystinuria cblC type", "Cobalamin C deficiency", "cblC deficiency", "Homocystinuria type III", "Methylenetetrahydrofolate reductase deficiency", "MTHFR deficiency" | 16 16 trials 6 / 9 / 0 / 1 💬 | 19 19 drugs [ 7 7 drugs ] | 2 2 genes 23 pathways | 11 (1) Type I (CBS deficiency): About 200 patients; Type II: Less than 100 patients; Type III: Less than 100 patients (2) 11 patients Age distribution💬 |
338 | Progressive familial intrahepatic cholestasis [Gast] 💬 "PFIC" | 60 60 trials 27 / 18 / 40 / 5 💬 | 26 26 drugs [ 6 6 drugs ] | 2 2 genes 2 pathways | 2 (1) About 100 patients (2) 2 patients Age distribution💬 |